

Guidance on Information Requirements and Chemical Safety Assessment

Part R.14: Occupational exposure assessment

Draft (Public) Version 3.0
June 2016



1 **LEGAL NOTE**

2 This document aims to assist users in complying with their obligations under the REACH
3 Regulation. However, users are reminded that the text of the REACH Regulation is the
4 only authentic legal reference and that the information in this document does not
5 constitute legal advice. Usage of the information remains under the sole responsibility of
6 the user. The European Chemicals Agency does not accept any liability with regard to the
7 use that may be made of the information contained in this document

8

9

Guidance on Information Requirements and Chemical Safety Assessment
Chapter R.14: Occupational exposure assessment

Reference: ECHA-XXXXXX-EN

ISBN: XXXXXX

Publ.date: XXXXXX

Language: EN

© European Chemicals Agency, 2016

If you have questions or comments in relation to this document please send them (indicating the document reference, issue date, chapter and/or page of the document to which your comment refers) using the Guidance feedback form. The feedback form can be accessed via the ECHA Guidance website or directly via the following link:

<https://comments.echa.europa.eu/comments/cms/FeedbackGuidance.aspx>

European Chemicals Agency

Mailing address: P.O. Box 400, FI-00121 Helsinki, Finland

Visiting address: Annankatu 18, Helsinki, Finland

1 Preface

2

3 This document describes the information requirements under the REACH Regulation with
4 regard to substance properties, exposure, use and risk management measures, and the
5 chemical safety assessment. It is part of a series of guidance documents that are aimed
6 to help all stakeholders with their preparation for fulfilling their obligations under the
7 REACH Regulation. These documents cover detailed guidance for a range of essential
8 REACH processes as well as for some specific scientific and/or technical methods that
9 industry or authorities need to make use of under the REACH Regulation.

10 The original versions of the guidance documents were drafted and discussed within the
11 REACH Implementation Projects (RIPs) led by the European Commission services,
12 involving stakeholders from Member States, industry and non-governmental
13 organisations. After acceptance by the Member States competent authorities the
14 guidance documents had been handed over to ECHA for publication and further
15 maintenance. Any updates of the guidance are drafted by ECHA and are then subject to
16 a consultation procedure, involving stakeholders from Member States, industry and non-
17 governmental organisations. For details of the consultation procedure, please see:

18 [http://echa.europa.eu/documents/10162/13559/mb_63_2013_consultation_procedure_f
or_guidance_revision_2_en.pdf](http://echa.europa.eu/documents/10162/13559/mb_63_2013_consultation_procedure_f
19 or_guidance_revision_2_en.pdf)

20 The guidance documents can be obtained via the website of the European Chemicals
21 Agency at:

22 <http://echa.europa.eu/web/guest/guidance-documents/guidance-on-reach>

23 This document relates to the REACH Regulation (EC) No 1907/2006 of the European
24 Parliament and of the Council of 18 December 2006¹ and its amendments until 27
25 December 2015.

¹ Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006).

1 **Document History**

2

Version 1	First edition	May 2008
Version 2	<ul style="list-style-type: none"> The material on worker exposure models in Part D of IR&CSA guidance (Chapter 5.3 and Appendix D-1 pp. 63-64) introduced to Chapter 14.4. 	May 2010
Version 2	<ul style="list-style-type: none"> In the text on exposure models "steps to run the tool" have been removed, as they were not considered helpful in written guidance. 	May 2010
Version 2	<ul style="list-style-type: none"> Section 14.4.7 on the ECETOC TRA worker tool for exposure estimation at Tier 1 has undergone a major revision and updating, with the inclusion of the new version of ECETOC TRA worker model 	May 2010
Version 2	<ul style="list-style-type: none"> The text on other models (Stoffenmanager, Riskofderm, ART) has been updated 	May 2010
Version 2	<ul style="list-style-type: none"> The text on EMKG-Expo-Tool has been edited 	May 2010
Version 2	<ul style="list-style-type: none"> The text on measurement data has been updated (R 14.4.4 and R14.4.5) 	May 2010
Version 2	<ul style="list-style-type: none"> A new Section R14.4.6 on short term exposure data has been introduced 	May 2010
Version 2.1	<p>Corrigendum:</p> <ul style="list-style-type: none"> (i) replacing references to DSD/DPD by references to CLP (ii) further minor editorial changes/corrections 	November 2012
Version 3.0	<ul style="list-style-type: none"> New sections on assessment workflow and assessment principles have been introduced (Sections R.14.3 and R.14.4) Section R.14.5 on Exposure determinants has been redrafted to include extended information on exposure scenarios and means of exposure control New Section R.14.5.4 on SWEDs has been introduced The section on measured data (R.14.6.3) has been redrafted to focus on principles to consider rather 	Xxxx 2016

	<p>than in number of data points required</p> <ul style="list-style-type: none">• The information on modelling tools (Section R.14.6.6) has been updated and streamlined• The BEAT model has been added to the list of tools (Section A.14-1.4.3 in Appendix R.14-1)• New section on exposure assessment for applications for authorisation has been added (Section R.14.7.)	
--	--	--

1

2

Notes on the updates

The updates in this guidance provide either additional tools and parameters to support occupational exposure assessment and exposure scenario building under REACH, or provide further explanation to improve understanding. Other revisions are of an editorial nature.

A registrant having already finalised the occupational exposure estimation based on versions 2 or 2.1 of Chapter R.14 may therefore wish to take the following advice into account:

- Carefully read the document history to be informed on what has been updated;
- Check whether the changes in the guidance put into question:
 - the scope of the exposure assessment and scenarios already worked out, and
 - the outcome of the risk characterisation related to these exposure scenarios.

In this respect, it should be highlighted that an assessment carried out with previous versions of the exposure estimation tools can still be considered valid.

Registrants may decide on reading this guidance, they need to update their CSR, if the issues cause them to revise their assessment. Some possible issues are identified below:

- **Use of exposure estimation tools:** sources of uncertainty when using estimation tools and the domain of applicability of the tools have been further detailed in guidance. (See Appendix R.14-1)
- **Risk management measures:** Section R.14.5.2 includes information on closed systems and ventilation. The closed systems sub-section includes advice on the assignment on PROCs used for rigorous containment (PROCs 1-3), whilst the ventilation sub-section explains the expected effectiveness associated with certain types of ventilation.
- **Acute exposures:** the updated guidance further clarifies the applicability of estimation tools for the assessment of acute exposures.
- **Glove material:** Section R.14.5.3 on PPE clarifies that an effective glove for the registered substance should be described in the IUCLID dossier

If the conclusion of the check is that the scope of the exposure assessment and scenarios are satisfactory and the outcome of the risk characterisation is also satisfactory, then it is unlikely that an already existing Chemical Safety Report would need to be updated or amended. If none of the substantive issues outlined here affects an already existing Chemical Safety Report, amendments are not required due to this guidance update.

1 **Convention for citing the REACH regulation**

2 Where the REACH regulation is cited literally, this is indicated by text in italics between
3 quotes.

4

5 **Table of Terms and Abbreviations**


6 See Chapter R.20

7

8 **Pathfinder**

9 The figure below indicates the location of chapter R.14 within the Guidance Document

10



11

1		
2	Table of Contents	
3	R.14 OCCUPATIONAL EXPOSURE ASSESSMENT	10
4	R.14.1 AIM OF THIS GUIDANCE	10
5	R.14.2 TYPES AND ROUTES OF EXPOSURE	10
6	R.14.2.1 Inhalation exposure	11
7	R.14.2.2 Dermal exposure	12
8	R.14.2.3 Oral exposure	13
9	R.14.3 ASSESSMENT WORKFLOW	14
10	R.14.4 ASSESSMENT PRINCIPLES	17
11	R.14.4.1 Determine the scope of exposure assessment	17
12	R.14.4.2 Particular case: Exposure considerations when determining testing needs	18
13	R.14.4.3 Integration of quantitative and qualitative hazard conclusions	18
14	R.14.4.4 Principles for determining the control strategy	19
15	R.14.5 EXPOSURE DETERMINANTS	20
16	R.14.5.1 Exposure scenarios and contributing scenarios	21
17	R.14.5.2 Technical means and administrative controls	22
18	R.14.5.2.1 Closed systems (rigorous containment)	22
19	R.14.5.2.2 Ventilation	23
20	R.14.5.2.3 Management controls	24
21	R.14.5.3 Personal protective equipment	25
22	R.14.5.4 Specific Worker Exposure Descriptions (SWEDs)	26
23	R.14.6 EXPOSURE ESTIMATION	27
24	R.14.6.1 Introduction	27
25	R.14.6.2 Assessment of data and information quality	28
26	R.14.6.3 Use of measured data	29
27	R.14.6.3.1 Representativeness of the data and variability of exposure	30
28	R.14.6.3.2 Analogous data	31
29	R.14.6.4 Selection and interpretation of measured data	32
30	R.14.6.4.1 General aspects	32
31	R.14.6.4.2 Inhalation data and sample size	33
32	R.14.6.4.3 Dermal data	35
33	R.14.6.4.4 Biological monitoring data	35
34	R.14.6.5 Assessment of acute exposures	36
35	R.14.6.5.1 Assessment of acute inhalation exposure	36
36	R.14.6.5.2 Acute dermal exposure assessment	37
37	R.14.6.6 Use of exposure estimation tools	38
38	R.14.7 EXPOSURE ASSESSMENT AND APPLICATIONS FOR AUTHORISATION	42
39	R.14.7.1 Special requirements of Applications for Authorisation (AfA)	42
40	R.14.7.2 Assessment of Chemical Safety Reports by RAC	44
41	APPENDIX R.14-1. EXPOSURE ESTIMATION MODELS	48
42	A.14-1.1. ECETOC TRA TOOL FOR OCCUPATIONAL EXPOSURE	48
43	A.14-1.2. MEASE FOR METALS AND INORGANIC SUBSTANCES	54
44	A.14-1.3. EMKG-EXPO-TOOL	56

1	A.14-1.4. HIGHER TIER EXPOSURE ASSESSMENT.....	58
2	REFERENCES	70
3		
4	Table of Figures	
5	Figure R.14- 1: workflow for occupational exposure assessment	14
6		
7	Table of Tables	
8	Table R.14- 1 Implications of the chosen information source	28
9	Table R.14- 2: Applicability matrix (inhalation models)	39
10	Table R.14- 3 Applicability matrix (dermal models)	40
11	Table R.14- 4: Contributing Scenarios presented in the Use	44
12	Table R.14- 5: Operational Conditions and Risk Management Measures	44
13	Table R.14- 6: Exposure – dermal and inhalation	45
14	Table R.14- 7: Combined exposure	45
15	Table R.14- 8: Domain of reliable application of the TRAv3.1	48
16	Table R.14- 9: ECETOC TRA Output.....	53
17	Table R.14- 10: Domain of intended application of MEASE 1.02.01 and MEASE 2	54
18	Table R.14- 11: MEASE output.....	56
19	Table R.14- 12: EMKG-Expo-Tool OUTPUT version 2.2	57
20	Table R.14- 13: Domain of reliable application of Stoffenmanager® (the algorithms can only be	
21	found at www.stoffenmanager.nl in its most recent version)	59
22	Table R.14- 14: Stoffenmanager output.....	62
23	Table R.14- 15: domain of applicability of ART	66
24	Table R.14- 16: ART output.....	68
25		
26		

R.14 Occupational exposure assessment

R.14.1 Aim of this guidance

This guidance gives advice to registrants on how to carry out an occupational exposure assessment under REACH. REACH requires, according to Article 14(4), exposure assessment and subsequent risk characterisation to be carried out for substances subject to registration, which are manufactured or imported in quantities equal to or greater than 10 tonnes/year, and where the substance fulfils the criteria for any of the hazard classes or categories listed in Article 14(4)² or is assessed to be a PBT or vPvB. It describes how to build the exposure scenario and estimate the exposure. The guidance also addresses aspects relating to the scope of the assessment, and the assessment workflow.

The guidance includes the following sections:

- [Types and routes of exposure](#) (Section R.14.2)
- [Assessment workflow](#) (Section R.14.3)
- [Assessment principles](#) (Section R.14.4)
- [Exposure determinants](#) (Section R.14.5)
- [Exposure estimation](#) (Section R.14.6)
- [Exposure Assessment and Applications for Authorisation](#) (Section R.14.7)
- [Exposure estimation models](#)
- (Appendix R.14-1)

The main focus of the guidance is occupational exposure assessment in the context of REACH Registration (i.e. when required by Article 14(4)). However, occupational exposure estimation is also required in the context of applications for authorisation and the information contained in this guidance is, in general, also applicable to the exposure assessment in this context with specific considerations identified in Section R.14.7.

R.14.2 Types and routes of exposure

Substances in the workplace may come into contact with the body and possibly enter the body by inhalation, by contact with the skin (dermal route), or sometimes by swallowing (ingestion/oral route).

Exposure estimation will need to consider the following three separate exposure routes:

- inhalation exposure: usually represented by the average airborne concentration of the substance over a reference period in the breathing zone of a worker;
- dermal exposure : the amount of substance in contact with the skin surface, and/or
- oral exposure: but only to consider in the context of proposing appropriate risk management measures and strategies to avoid exposure in specific cases.

² These are:

- hazard classes 2.1 to 2.4, 2.6 and 2.7, 2.8 types A and B, 2.9, 2.10, 2.12, 2.13 categories 1 and 2, 2.14 categories 1 and 2, 2.15 types A to F
- hazard classes 3.1 to 3.6, 3.7 adverse effects on sexual function and fertility or on development, 3.8 effects other than narcotic effects, 3.9 and 3.10
- hazard class 4.1
- hazard class 5.1

1 A fraction of the amount in contact (external exposure) will be absorbed into the body,
2 either via the digestive system, the respiratory tract, or through the skin and can cause
3 systemic effects (internal dose). This fraction is usually route and substance specific but
4 may also depend on other factors. If no specific information is available, 100% is
5 assumed.

6 Exposure to a particular substance is normally determined through estimating the
7 "external" exposure, which needs to be compared to a toxicological threshold (DNEL) for
8 quantitative risk characterisation. This may refer to local effects at the point of entry or
9 to systemic effects. The DNELs for systemic effects are also expressed as external
10 concentration or dose, in order to facilitate direct comparison. Depending on the
11 available information such DNELs already takes into account the fraction of substance
12 absorbed into the body. When extrapolating systemic study results from one exposure
13 route to another, the route specific absorption behaviour needs to be taken into account
14 (See *Chapter R.8 of the Guidance on IR&CSA* [1]).

15 The routes of exposure and the nature of effect will dictate the risk management
16 strategy that needs to be deployed. (See Section R.14.4.4).

17 In addition to the exposure routes, the duration and frequency of exposure after which
18 the effect occurs (acute or chronic effect) needs to be taken into account. Acute effects
19 (e.g. narcosis, irritation) occur rapidly as a result of short-term exposures while chronic
20 effects generally occur as a result of long-term exposure (months, years) etc.

21 For comparison with hazards after repeated or continuous exposure (chronic effects), a
22 reference period of a full shift (normally 8 hours) is generally used. Exposures that are
23 typically longer or shorter than the 8-hour reference period can be adjusted in
24 magnitude to provide an 8-hour time-weighted average estimate so they can be
25 compared with chronic DNELs. If the substance has the potential to cause acute health
26 effects (leading to classification), the peak exposure over shorter reference periods must
27 be identified and evaluated and compared with an acute DNEL. This is often a 15-minute
28 time weighted average exposure to be compared with the corresponding (15 min) acute
29 DNEL. Shorter exposure periods may be more appropriate depending on the effect.
30 Section R.14.6 on exposure estimation provides advice on how to assess the long-term
31 exposure and gives specific advice for the assessment of acute exposures in Section
32 R.14.6.5.

33 For certain effects, like for example irritation or corrosion to skin and eyes usually no
34 exposure estimate and risk quantification is needed to demonstrate control of risk. For
35 uses of acids and bases in mixtures for example, control of local risks may be achieved
36 by limiting the concentration to the classification threshold for mixtures, or by the
37 presence of a buffer system in the mixture. The registrant is expected to provide
38 arguments that the conditions of use described in the exposure scenario make it unlikely
39 that adverse effects occur (qualitative risk characterisation). The same applies for other
40 effects where no threshold can be derived.

41 **R.14.2.1 Inhalation exposure**

42 Inhalation exposure is generally expressed as mg/m³ for particulates and in ppm (parts
43 per million) or mg/m³ for volatile substances. It may be sometimes useful to express
44 exposures as ppm for vapours, especially when data are to be used in analogous
45 situations – a conversion can then be made to account for molecular weight. Other
46 metrics could also be relevant, such as cm²/m³ (relevant for nanomaterials) and/or
47 particle number/cm³ (especially relevant for fibres and also relevant for nanomaterials).

48 When assessing the exposure arising from aerosols (liquid and solid, including fumes,
49 dust, and fibres), some considerations may need to be taken into account such as the
50 aerodynamic particle size. Particle size may vary with time and place (for instance,
51 when arising from processes such as evaporation, condensation or settling of particles).

1 Particle size is important because, firstly it determines the uptake, as some particles will
2 not be inhaled due to their size. Secondly, once the particles are inhaled, the particle
3 properties will determine the most likely location of deposition in the respiratory tract;
4 which will in many cases determine the possible adverse health effects. For example, for
5 an aerosol that is soluble in human fluids and can therefore be absorbed and have
6 systemic effects, the whole amount of the substance inhaled, is relevant regardless of
7 the particle size. However, for particles having an effect by accumulation in a specific
8 area of the respiratory tract (may be regarded as local effects), only the particles within
9 a certain size-range may be of interest in the exposure assessment. Examples of
10 aerosols causing local effects in specific lung regions include crystalline silica on the
11 alveolar region (respirable fraction, see below), causing silicosis, or sulphuric acid mist
12 deposited in the thoracic region.

13 It does not mean the particle size distribution of the aerosol needs to be known in every
14 situation. The general approach in occupational sites has been to use mass fractions
15 (e.g., health related fractions as defined by EN 481) except in the case of fibres. For
16 example, in Europe, from the publication of the EN 481 the OELs for powder materials
17 have been defined for one or several mass fractions (inhalable, thoracic or respirable).
18 Thus, if measurements of airborne dusts take place, it should be indicated for which
19 aerosol fraction(s) (inhalable, thoracic or respirable as defined by the European standard
20 EN 481 [2]) the measurements have been performed.

21 The assessment of exposure to aerosols that show mixed phases is more challenging and
22 there is limited experience on how to tackle it . For example, in the case of volatile
23 substances, the exposure assessment may need to take into account components that
24 are both vapour and aerosol – either form may dominate the assessment, depending on
25 the uses and the characteristics of the substance. The European standard EN 13936 [3]
26 provides advice on health-related sampling of mixed-phase aerosols, including advice on
27 which phase(s) matters depending on the substance properties and the conditions of
28 use. The CONCAWE report 8/15 [4] describes sampling and analysis methods for
29 measurement of the personal exposure concentration of gas oil vapours and aerosols

30 The general requirements for methods to determine the concentration of airborne
31 chemicals in the workplace are well described in European standards (e.g. EN 482 [5])
32 and are normally supported by published methods at a national or international level
33 validated against the standards³.

34 **R.14.2.2 Dermal exposure**

35 Substances may have local effects on the skin or may have the ability to penetrate skin
36 (both intact and broken) and become absorbed into the body. The following two terms
37 can be used to describe dermal exposure:

- 38 • **potential dermal exposure (PDE)** is an estimate of the amount of the
39 substance or mixture being deposited on both the unprotected and protected
40 body parts. It is the total amount of contaminant landing on the outside of work-
41 wear and on the exposed surfaces of the various protected and unprotected skin,
42 including hands, torso, face, neck and even feet;

³ The GESTIS database contains validated lists of methods from various EU member states described as suitable for the analysis of chemical agents at workplaces (<http://www.dguv.de/ifa/GESTIS/GESTIS-Analysenverfahren-für-chemische-Stoffe/index.jsp>).

- 1 • **actual dermal exposure (ADE)** is an estimate of the amount of contamination
2 deposited on the skin.

3 In regulatory assessment of chemicals, the current approach is to make an estimate to
4 assess actual dermal exposure – i.e. what gets onto the skin. Potential dermal exposure
5 is the most frequently available indicator of amount of deposition arising from real data
6 and can be used to establish the necessary risk management measures (RMM) required
7 to predict actual dermal exposure and demonstrate a safe use.

8 Dermal exposure is highly variable and often unpredictable; for example, it is often
9 made up of splashes and smears and not an idealised evenly spread layer on the skin, or
10 it may occur from spraying an aerosol that generates a high concentration which is then
11 deposited widely on the exposed skin and clothing.

12 Dermal exposure may occur through direct skin contact with surfaces that have been
13 previously contaminated. The three major routes of dermal contamination are:

- 14 • by deposition (from air),
15 • by direct contact with the contaminant (e.g. immersion, splashes), and
16 • by contact with contaminated surfaces (including clothing).

17 The level of dermal exposure is generally expressed in mg/kg bw/day (for systemic
18 effects) and as a rate of contamination e.g. in mg/minute or $\mu\text{l}/\text{minute}$ of a substance
19 depositing as potential dermal exposure or sometimes as dermal load in terms of the
20 mass of contaminant per unit surface area of the skin exposed ($\mu\text{g}/\text{cm}^2$ or mg/cm^2).
21 Estimates of deposition may be arrived at through multiplying the rate of deposition
22 (mg/min) by the duration of the task. Mg/cm^2 may be a common metric for substances
23 that are applied to the skin in a known dose but, in an industrial context, such uniform
24 application or deposition is rather unlikely.

25 In general, the quantitative assessment should be considered in the context of the
26 uncertainties that exist. Proposals for personal protective measures for dermal exposure
27 and especially for substances considered of high risk through the combination of hazard
28 profile and potential for skin absorption will need to take this into account. It is better if
29 the risk management strategy is decided first and the required measures are then
30 reflected in the quantitative assessment.

31 **R.14.2.3 Oral exposure**

32 Oral exposure in the workplace is usually unintentional ingestion and is addressed
33 through application of good occupational hygiene practice. In some cases where
34 substances present particularly high risk by the oral route it may be necessary to
35 consider specific RMM to prevent such exposure, or to implement measures that can
36 warn when unacceptable oral exposure could occur. Quantitative estimation of
37 unintentional ingestion is not required under REACH.

38 Unintentional ingestion exposure is important to consider when substances are, for
39 example, accumulated in the body over time causing toxic effects. Unintentional
40 ingestion usually occurs when substances are transferred from contaminated surfaces
41 (including hands and gloves) to the peri-oral region of the face or through direct
42 exposure resulting from aerosol release. Aerosols are, however, considered under
43 exposure via inhalation.

44 It is not routinely possible to estimate exposure by the oral route quantitatively.

45 Where identified as a key route, oral exposure can be addressed through a qualitative
46 approach aiming to identify the correct RMMs for each specified exposure scenario.
47 Where substances have a cumulative toxic effect, and where a method is available, it
48 may be possible to use biomonitoring as a means to assess the effectiveness of RMM

1 through demonstration of absence of significant uptake and providing assurance over the
 2 effectiveness of the workplace control strategy. Whatever approach is taken, the
 3 measures will always need to include effective occupational hygiene controls in the
 4 workplace.


5

6 R.14.3 Assessment workflow

7 The chemical safety assessment with regard to workers usually includes the steps
 8 explained below. The collection of information on the intrinsic properties of the substance
 9 and the hazard assessment is not addressed in this guidance but is mentioned because it
 10 generates information that is needed for the exposure assessment and risk
 11 characterisation.

12 The following flowchart (Figure R.14- 1) illustrates the steps described below; the light
 13 blue box contains all the steps related to the occupational exposure assessment (thus
 14 within the scope of this guidance), while the other boxes are related to other steps in the
 15 safety assessment that have an impact on the risk characterisation and are outside the
 16 scope of this guidance. The dotted red arrows show the different possibilities for the
 17 iteration of the assessment

18 **Figure R.14- 1: workflow for occupational exposure assessment**



- 1
- 2 • Collect information related to the intrinsic properties of the substance including:
- 3 ○ physicochemical properties (e.g. physical form, vapour pressure, water
- 4 solubility, dustiness);
- 5 ○ consider how the use conditions (e.g. process temperature, mechanical
- 6 energy, concentration of substance in the mixture) may impact on vapour
- 7 pressure, the (physical) form and the composition of the substance, including
- 8 reaction products that may occur. This may affect the conclusions on the
- 9 likely routes of exposure that need to be assessed.
- 10 ○ toxicological outcomes (e.g. irritation, sensitisation, acute and chronic
- 11 systemic effects, genotoxicity, carcinogenicity, reproductive toxicity);
- 12 • Determine the type and the severity of hazards, through classification and labelling
- 13 and by deriving no-effect levels (DNELs) or derived minimal effect levels (DMELs)⁴
- 14 (See *Part B and Chapter R.8 of the Guidance on IR&CSA* [6] and [1]).
- 15 • Determine the leading hazard for each exposure route to be addressed in the
- 16 exposure assessment. It may be necessary to address both local and systemic effects
- 17 at the same time.
- 18 • Determine the scope of exposure assessment (informed by hazard conclusions) (See
- 19 Section B.8 of *Part B of the Guidance on IR&CSA* [6]):
- 20 ○ Determine whether (serious) local effects on skin, eyes, respiratory tract may
- 21 occur (e.g. due to irritation, corrosion or sensitisation).
- 22 ○ Determine whether short-term high exposure events can cause serious
- 23 systemic effects;
- 24 ○ Determine routes and types of effects for which exposure quantification is
- 25 required (i.e. where a DNEL/DMEL can be derived based on effects seen in the
- 26 corresponding study(s).
- 27 • Determine control strategy based on substance properties, hazard conclusions and
- 28 use patterns: for example consider whether rigorous containment (or other means to
- 29 prevent contact) is the required option; determine whether acute exposure may need
- 30 to be addressed; determine the engineering controls required to reduce exposure
- 31 below the DNEL/DMEL; determine where local effects can be prevented by limiting
- 32 the concentration of the substance in a mixture;
- 33 • Define an exposure scenario for each use along the life cycle of the substance: Build
- 34 a set of contributing scenarios (see Section R.14.5.1) for all tasks or processes under
- 35 this use, relevant to worker exposure) ; start from the typical conditions currently
- 36 found in the sectors of use; employ use maps and exposure assessment inputs
- 37 available from DU sector organisations (e.g. sector specific exposure descriptions,
- 38 SWEDs; or sector Generic Exposure Scenarios) or obtain information from customers
- 39 that represent specific uses of the substance; See ECHA's illustrative example for
- 40 CSR [7]
- 41 • Derive quantitative exposure estimates for all contributing scenarios where needed to
- 42 support the risk characterisation (i.e. where DNELs/DMELs have been determined in
- 43 the hazard assessment, and/or where the functioning of rigorous containment should
- 44 be demonstrated). The exposure estimates can be based on modelling tools, or on
- 45 measured data sets. It needs to be ensured, that the conditions described in the
- 46 exposure scenario are consistent with the applicability domain of the modelling tool

⁴ DNELs represent the level of exposure above which humans should not be exposed. DNELs are derived for substances based on: population (workers, consumers and the general population), route (inhalation, dermal and ingestion exposure) and duration (acute and long-term exposure)

For non-threshold effects (e.g. non-threshold mutagens and non-threshold carcinogens) a no-effect level, and thus a DNEL, cannot be established. However, it may be possible, if data allow, to set a DMEL (derived minimal effect level), a reference risk level considered to be of very low concern

- 1 or with the conditions under which the measured data set has been obtained.
- 2 • Derive risk characterisation ratios (RCRs) per route and relevant type of effect.
- 3 Derive combined risk characterisation ratio (RCR) for dermal and inhalation exposure
- 4 if systemic effects are relevant.
- 5 • Where qualitative risk characterisation is required, provide the key arguments why
- 6 the conditions of use described in the exposure scenario are appropriate to
- 7 limit/prevent exposure. Quantitative estimates of exposure are also helpful to
- 8 support judgement on RMMs and OCs.
- 9 • Conclude whether further refinement of assessment is needed, and finalise the risk
- 10 characterisation (quantitative and/or qualitative).
- 11 •
- 12 Document the assessment in the CSR. Communicate conditions/measures for safe
- 13 use down the supply chain. Ensure that customers receive information that is
- 14 consistent with the CSR and can be interpreted in the workplace. This should also
- 15 cover uses far down the supply chain where the concentration of a substance in a
- 16 mixture is below the classification thresholds, but still the properties of the substance
- 17 are such that workers would need particular advice to avoid health effects.
- 18 .
- 19
- 20
- 21

1

2 **R.14.4 Assessment principles**

3 **R.14.4.1 Determine the scope of exposure assessment**

4 The starting point for the registrant's exposure assessment is the outcome of the hazard
5 assessment, which is based on the endpoint information required under REACH. The
6 adverse effects identified for the substance determine the scope of the exposure
7 assessment. In the hazard assessment the registrant should already have taken into
8 account the likely routes of exposure, including consideration of the intrinsic properties
9 of the substance (e.g. volatility, physical state, forms of the substance) and the
10 anticipated conditions of use. The tendency for a substance to be absorbed through the
11 skin may already have been considered in the hazard assessment.

12 For workers, the output of the hazard assessment consists of nine conclusions referring
13 to the various combination of exposure route, location of effect and time needed to
14 trigger the effect (see *Chapter B.8 of the IR&CSA Guidance* [6])

- 15 • types of effect (local on skin, in respiratory tract or eyes, or systemic effect)
- 16 • the duration and frequency of exposure after which the effect occurs (acute or
- 17 chronic effect)
- 18 • the routes of exposure (inhalation, dermal, oral, eyes)

19 The outcome conclusion for each route and type of effect may be one of the following:

- 20 • No hazard has been identified. Consequence: no exposure assessment is needed
- 21 • Insufficient data are available to conclude on the hazard. Consequence: a testing
- 22 proposal has been made and the exposure assessment needs to identify suitable
- 23 interim measures to control the risk.
- 24 • Exposure is demonstrated to be negligible, and testing is therefore considered not
- 25 needed (exposure based adaptation). A comprehensive justification should be
- 26 provided: conditions of use (including exposure controls) to be described
- 27 ensuring that the exposure is negligible, and quantification of the expected
- 28 exposure level under these conditions.
- 29 • DNEL/DMEL can be derived quantifying the level of exposure where no effects are
- 30 expected or where the likelihood of adverse effects is sufficiently low.
- 31 Consequence: suitable exposure controls to be determined and corresponding
- 32 exposure estimates to be derived, demonstrating that the expected exposure is
- 33 below the DNEL/DMEL. If a DMEL is used as a reference, an additional
- 34 argumentation is needed why the exposure level represented by the DMEL leads
- 35 to tolerable health risk.
- 36 • No DNEL/DMEL can be derived, but other toxicological threshold (e.g. a
- 37 Toxicological Threshold of No Concern) is available for comparison with exposure
- 38 estimate. Consequence: depending on the type of threshold it can be used as a
- 39 surrogate DNEL (justification required) or a reference for assessing the level of
- 40 expected exposure in a more qualitative way.
- 41 • No DNEL/DMEL can be derived, but the level of hazard is concluded from
- 42 classification of the substance. Consequence: Suitable exposure controls to be
- 43 determined and qualitative argumentation needed why the measures are
- 44 appropriate to ensure a low/tolerable likelihood of adverse effects. The
- 45 physicochemical properties of the substance and its form during use are to be
- 46 taken into account. Depending on the case, the expected exposure may benefit
- 47 from being quantified to support the argumentation.
- 48 • For cases where the substance is corrosive or irritating to skin or eyes and where
- 49 no information from an inhalation study on respiratory tract irritation is available,
- 50 it should be appropriate to assume an irritation hazard also for the inhalation
- 51 route. For substances identified as potential skin sensitizers, it is also advisable to

1 take steps to prevent/minimise inhalation exposure. For low molecular weight
2 substances identified as respiratory sensitizers, it is appropriate to consider
3 measures to prevent skin contact even if a specific hazard for the skin has not
4 been identified.

5 By definition the systemic DNEL/DMELs derived under REACH are meant to be expressed
6 as external concentration (mg/m^3 for inhalation) or deposition on skin (mg/cm^2 or mg/kg
7 bw/day). Depending on the underlying toxicity data, such values may be based on the
8 assumption that:

- 9 • 100% of the inhaled/deposited substance is transferred into the body or
- 10 • limited defined absorption into the body takes place.

11 If 100% absorption is assumed the derived DNEL is lower than the case where a DNEL is
12 derived where partial absorption has been taken into account. Thus, when characterising
13 the risk, the factors determining the DNEL need to be taken into account.

14 A comparable issue may occur when inhalation exposure of a dust/aerosol is to be
15 assessed against a local DNEL for the deep lungs. Unless information on the particle size
16 distribution or the aerosol fraction occurring in the workplace is available, it should be
17 assumed that all particles are respirable (i.e. penetrate into alveolar region in the lungs).
18 Also, the particle size distribution of the airborne fraction released during use may be
19 different from the distribution measured from stored samples of the manufactured
20 material or from the test material in the toxicity study.

21

22 **R.14.4.2 Particular case: Exposure considerations when** 23 **determining testing needs**

24 The exposure assessment may, on occasions, be used as a means to help determine the
25 most appropriate route for administration during testing. The physicochemical
26 properties of the substance and uses may lead to the conclusion that significant
27 inhalation exposure is or is not expected (e.g. as a result of vapour pressure). In these
28 cases, it should be clear from the conditions described in the exposure scenario when,
29 for example, processing at elevated temperatures or when aerosol formation is
30 predicted, that the correct conclusions are drawn. Extending the exposure scenarios into
31 unnecessary uses may lead to the wrong conclusion on route of administration –
32 especially by inhalation when it does not really exist to a great extent.

33 On occasions you may wish to rely on an exposure assessment to support a case for
34 either a column 2 adaptation or for substance-tailored exposure-driven adaptation
35 (Annex XI, Section 3).

36 Generally the need is to demonstrate that there is sufficient evidence of absence of
37 exposure, as defined through the application of strictly controlled conditions (Article 18.4
38 (a) to (f)). Advice on how measurements may support an argument for strictly
39 controlled conditions and absence of exposure is presented in *Practical Guide 16: How to*
40 *assess whether a substance is used as an intermediate under strictly controlled*
41 *conditions and how to report the information for the intermediate registration in IUCLID*.
42 Various terms are used in the legal text as an indicator of the standard to be achieved,
43 but in every case the evidence will need to be specific, adequate and suitable for that
44 purpose. It is unlikely that exposure modelling alone will provide the level of proof
45 required to demonstrate these highly controlled and rigorously contained conditions.

46

47 **R.14.4.3 Integration of quantitative and qualitative hazard** 48 **conclusions**

49 Having DNELs or DMELs for all the required and available data on a substance makes it

1 fairly easy to identify the leading health effect for that substance for the relevant
2 exposure patterns. By contrast, for a substance having DNELs or DMELs for some
3 endpoints and data of a qualitative nature for other endpoints, it may be more
4 challenging to identify the leading health effect for each route for the relevant exposure
5 patterns.

6 The general approach when it is not possible to derive a DNEL or DMEL for an endpoint,
7 is to reduce/avoid contact with the substance. However, implementation of risk
8 management measures (RMMs) and operational conditions (OCs) needs to be
9 proportional to the degree of concern for the health hazard presented by the substance.
10 For example, it is not appropriate to apply the same control strategy to irritating
11 substances as to substances that are strong respiratory sensitizers or mutagenic.

12 A typical assessment situation in this respect occurs if a substance may cause local
13 effects in the respiratory system due to its properties (but no DNEL available) and
14 causes systemic effects at the same time (for which an inhalation DNEL has been derived
15 by route to route extrapolation). Often it may not be obvious upfront, which of the two
16 effects would drive the risk management, and thus a concentration level at which local
17 effects may occur needs to be estimated.

18 This means that the conditions of use (OCs and RMMs) as set out in the exposure
19 scenario (that determine the exposure level) need to reflect the severity of the hazard.
20 The severity of the hazard (and consequently the suggested extent of exposure controls)
21 may be indicated:

- 22 • by one of the three hazard-levels (high, moderate or low) suggested in *Part E of*
23 *the IR&CSA Guidance* [8] and based on the EU hazard classification system
24 (hazard statements). These hazard levels reflect three factors:
 - 25 i) whether a threshold theoretically exists but available data do not allow to set
26 a DNEL (e.g. for irritation);
 - 27 ii) the seriousness of the health effect and
 - 28 iii) the potency of the substance regarding a certain effect (e.g. strong
29 sensitizer versus moderate sensitizer);
- 30 • and additionally by a DMEL (if available)

31 Based on DNELs, DMELs and the Classification and Labelling based hazard bands it
32 should be possible to identify the critical hazard for each route of exposure and type of
33 effect.

34 For more details see *Part E of the IR&CSA Guidance* [8], [Table E.3-1](#).

35

36 **R.14.4.4 Principles for determining the control strategy**

37 The purpose of the exposure assessment in the CSR for registration is to describe the
38 conditions for safe use under normal operating conditions. It assumes good practice in
39 compliance with national occupational health and safety legislation. Based on this, the
40 exposure estimates should be representative of the safe use conditions described.

41 Exposure resulting from misuse or abuse would not normally be considered during the
42 assessment. Similarly, exposure which results from accidental release and serious failure
43 of plant integrity leading to major loss of containment, does not need to be addressed in
44 the exposure assessment.

45 The exposure assessment includes identifying the relevant exposure scenarios which can
46 be based on knowledge of own use, information from key customers, or use maps
47 developed by sector organisations (see Section 14.5.3). Depending on the routes of
48 exposure, the nature of effect and the availability of data to determine a safe level of

1 exposure, the appropriate control strategy can be determined. The principles for
2 determining the control strategy are as follows, in order of priority (according to
3 Directive 98/24/EC):

- 4 • Avoid any contact with the substance by containment and other strict controls;
5 for example, applicable for substances classified as mutagens, non-threshold
6 carcinogens, respiratory sensitizers, potent skin sensitizers and strong corrosives;
- 7 • Apply engineering controls (e.g. containment of the source, local exhaust
8 ventilation (LEV), mechanical ventilation ; conditions avoiding splashes, spills and
9 hand contact) to limit exposure to i) a safe level (if exposure can be compared
10 with DNEL/DMEL) or ii) a level where the likelihood of effects occurring is
11 sufficiently low (for qualitative assessment);
- 12 • Limit concentration of substances in mixtures when possible such that:
 - 13 ○ the classification thresholds for corrosion, irritation, sensitisation in
 - 14 mixtures is not exceeded;
 - 15 ○ the external concentration/loading of the substance is limited to a safe
 - 16 level for systemic exposure (to be verified by estimation of exposure).
- 17 • Apply management controls (e.g. reduction of the duration of the task)
- 18 • Apply appropriate personal protective equipment (PPE). It is important to note
19 that PPE is always the last resort;

20 The operational conditions including the control strategy for the highest hazard on a
21 given route will also be protective for lower hazards on the same route. Depending on
22 the properties of the substance, a threshold effect (quantitative assessment) or a non-
23 threshold effect (DNEL cannot be derived) can be the leading hazard.

24 If control of risk can be demonstrated for all routes and types of effect, the existing
25 conditions of use are obviously sufficient. Where the DNEL/DMEL is exceeded, or the
26 measures in place do not limit the likelihood of effects occurring at a low level, the
27 corresponding exposure scenarios need to be refined until safe use is guaranteed.

28 **R.14.5 Exposure determinants**

29 Worker exposure is determined by many factors, including:

- 30 • inherent properties of the substances, in a mixture or in an article;
- 31 • the process type and the associated containment and degree of engineering
32 control;
- 33 • operational conditions, e.g. temperature, in-use concentration, scale of use,
34 duration and frequency;
- 35 • RMMs applied and the associated effectiveness.

36 To enable robust worker exposure estimation the following type of information is
37 required:

- 38 • where is the substance used?
 - 39 ○ enclosed processes or plants;
 - 40 ○ indoor controlled environment;
 - 41 ○ indoor open sources;
 - 42 ○ outdoor; etc.
- 43 • how is the substance used?
 - 44 ○ high energy processing (e.g. spraying, grinding, hot processes) or low
 - 45 energy processing (e.g. assembly of article components, dipping of
 - 46 articles into bat);
 - 47 ○ remote or intimate contact during normal operation; etc.

- 1
- 2 • what are the operational conditions?
- 3 ○ characteristics of the substance (physical state/dustiness/vapour
- 4 pressure)and its concentration in a mixture or an article (process
- 5 materials, and finished products) under the operational conditions;
- 6 ○ duration and frequency of task;
- 7 ○ duration and frequency of exposure
- 8 ○ temperature of plant, process and surfaces; etc.
- 9 • what are the appropriate RMM?
- 10 ○ engineering controls;
- 11 ○ separation of operator from the emission points (cabin, control room);
- 12 ○ impact of management systems (e.g. housekeeping, operators
- 13 effectively trained in use of RMMs);
- 14 ○ personal protective equipment (PPE) (provided to address residual risk,
- 15 must be suitable and adequate ⁵ and associated with appropriate levels
- 16 of instruction and training); etc.

17 **R.14.5.1 Exposure scenarios and contributing scenarios**

18 For each of the identified uses in the life-cycle of a substance, the operational conditions
19 and risk management measures ensuring control of risk must be determined. This set of
20 information is called exposure scenario (ES). An exposure scenario usually covers a
21 number of contributing tasks/activities within the use (such as transfer, mixing,
22 spraying, dipping, brushing, cleaning of equipment/machinery etc.). A set of conditions
23 of use addressing one task/activity is called contributing scenario (CS).

24 The contributing activities (described by a name and a process category) usually do not
25 lead to the same exposure and do not necessarily take place under the same conditions
26 of use (e.g. duration, ventilation, dermal protection). Therefore, usually a contributing
27 scenario is generated for each of the activities/tasks, and corresponding exposure
28 estimates are derived. Where all the activities contributing to a use take place under
29 same conditions, they are still to be described and assessed one by one, when the
30 activity category or process category (PROC) as such drives the exposure estimate.

31 When the assessment is based on measured data, it is often the case that these
32 measured data have been collected across several different tasks over a shift. In this
33 case, the contributing activities that are relevant for the exposure scenario must still be
34 described one by one, even if it is not possible to identify data points from the measured
35 data set that are applicable to individual contributing activities. If the conditions are the
36 same across all tasks, the contributing activities may be linked to one set of use
37 conditions, which correspond to the conditions that are represented by the measured
38 exposure data (covering both routes of exposure).

39 For a given use (and its contributing activities), different levels of exposure controls may
40 be needed, depending on the hazard characteristics of the substance. The registrant is
41 expected to choose the appropriate level of control that matches the properties of the
42 substance (see also Section R.14.5.4 on SWEDs). It may also be appropriate to include

⁵ **Suitable** means the right type of equipment taking into account operational conditions and personal factors.
Adequate means capable of providing the right level of protection.

1 contributing scenarios for different concentration levels of the substance, when this gives
2 rise to different RMMs.

3 For most uses, manual cleaning and maintenance of equipment is needed from time to
4 time. This will include, for example, interventions into closed systems and cleaning of
5 machinery and vessels between batches. It may also include changing of filters,
6 maintenance of reservoirs of processing fluids and similar tasks. The exposure
7 assessment should include a contributing scenario describing conditions for this periodic
8 (but not necessarily daily) cleaning and maintenance if such activities are not already
9 covered in one or more of the other contributing scenarios. Repair due to accidental
10 malfunction or renovation/reconstruction of production plants is however out of scope of
11 the REACH safety assessment. . The exposure assessment is required for both the
12 substance to be removed, and any substances used as cleaning agent. However these
13 activities will normally be addressed by different registrants.

14 The updated *Chapter R.12 of the IR&CSA Guidance* [9] includes a new PROC (PROC 28)
15 to be assigned to this type of activities.

16 **R.14.5.2 Technical means and administrative controls**

17 RMMs are a combination of design, engineering solutions and the administrative
18 measures that deliver the required acceptable level of exposure.

19 Within the CSR, RMMs are required to be described; this is usually in generic terms such
20 as LEV or personal protective equipment. These descriptions are interpreted in the
21 workplace within the context of Chemical Agents Directive (98/24/EC). The Directive
22 establishes a hierarchy in the application of control measures, this means that
23 engineering controls such as closed systems, containment and use of ventilation
24 arrangements (local exhaust at the point of emission and/ or general building ventilation
25 (passive or mechanical) and) are always the preferred primary means to control
26 exposure.

27 A substantial amount of occupational health and safety guidance is widely available that
28 provides information on conditions for safe use in the workplace⁶. Registrants are
29 encouraged to link the RMMs in the CSR and in the ES for communication to such advice
30 when possible. Information from downstream user sector organisation can support this
31 (see also Section R.14.5.4).

32 **R.14.5.2.1 Closed systems (rigorous containment)**

33 Closed systems (including rigorous containment by technical means) generally relate to
34 high integrity plant/machinery where the opportunity for exposure is negligible, both in
35 terms of frequency and magnitude. Fugitive emissions do not occur under normal
36 conditions of use and only occur due to loss of integrity and associated failures in the
37 monitoring and management systems.

38 This section provides some particular guidance on the selection of a suitable PROC when
39 describing uses and its contributing activities in closed processes (for more information
40 on description of uses and for complete list of PROCs please see *Chapter R.12 of the*
41 *IR&CSA Guidance* [9]). At the same time reference is made to the applicability domain of
42 the PROC 1 to PROC 3 when used as an input parameter to exposure estimated based on
43 ECETOC TRA worker or other tools (See section A.14-1.1).

44 PROCs 1 to 3 refer to systems/plants that are intended to be closed (rigorously
45 contained), such as synthesis of substances in closed reaction and purification vessels,

⁶ See for example: https://oshwiki.eu/wiki/Hierarchy_of_controls_applied_to_dangerous_substances

1 drying towers or extraction of substances in distillation plants, where all transfers take
2 place via fixed pipes. Releases may result from planned interventions (e.g. cleaning and
3 maintenance, sampling), and if so, these would need to be assessed and managed
4 separately. However, if such processes are not undertaken under contained/closed
5 conditions PROCs 1 to 3 are not applicable, (e.g. for tray drying, dry milling and sieving,
6 manual charging/discharging to and from containers, filter presses, stirred reactions in
7 open or partially closed vessels), and a more suitable PROC, such as PROC 4 or PROC
8 8a/8b could be used.

9 Other process types occurring on end-use of substances (e.g. spraying, dipping,
10 brushing, printing, lubricating) may be engineered using containment, automation, and
11 ventilation so that a very low level of exposure can be achieved. When correctly
12 operated, the exposure can be similar to that associated with processes/plants referred
13 to as PROC 1 to PROC 3. However, it is not appropriate to just assign a PROC 1 to 3 in
14 such cases: The name of the contributing activity/scenario should clearly refer to the
15 actual type of process/task (e.g. industrial automated dip coating in closed system), the
16 assigned PROC should correspond to the type of process (e.g. PROC 13), and the closed
17 conditions need to be specifically described in the contributing scenario. An exposure
18 estimate based on PROC 1 to 3 may be applicable, but would need an explicit
19 justification. For the criteria that need to be checked and documented, see Section
20 A.14-1.1.1 on applicability domain of ECETOC TRA. For further description of the
21 different levels of containment, please refer to Section 2.1.1 of the ECHA *Guidance on*
22 *Intermediates*⁷ [10].

23 Enclosure, containment and process ventilation are most often inherent design features
24 of the plant. When managed effectively, these combined features have the potential to
25 prevent releases. Higher tier models allow assessment of these types of circumstances.

26 Please note: The information on whether a substance is used under rigorous
27 containment (only) may play a role for selection when identifying priority substances for
28 one or more of the REACH processes following registration. Therefore, IUCLID 6 includes
29 the possibility to explicitly flag to the authorities that a use takes place under rigorous
30 containment. For claiming such conditions of use, the registrant would need to describe
31 the containment and the related administrative controls in two dedicated fields of the
32 IUCLID dossier.

33 **R.14.5.2.2 Ventilation**

34 Additional control of emissions through the use of ventilation arrangements is often
35 ascribed a level of effectiveness (such as 80%, 90%, 95%) and mostly applies within the
36 context of processes where there is anticipated release, with a subsequent need to
37 control emissions at source. The levels of effectiveness will in themselves be associated
38 with aspects of design, commissioning, maintenance, monitoring etc., to prove they
39 deliver the necessary level of control. It is anticipated at well managed processes LEV
40 would, in any case, be subject to periodic examination and testing to demonstrate the
41 level of performance.

42 Effectiveness of LEV is determined by many factors such as type of emission, design of
43 the enclosure, positioning of the worker and the correct flow of air throughout the
44 system. This is to ensure that capture performance and transport of the substance is
45 optimal. Best performance is associated with maximising enclosure, integration of
46 ventilation arrangements into the process, good design, commissioning and
47 management. Levels of effectiveness of LEV can however, be difficult to establish with
48 certainty.

⁷ Please note that above mentioned section describes containment systems in general, not only closed systems

1 However, the characteristics generally associated with certain levels of effectiveness can
2 be identified:

3 95% effectiveness or higher is, ordinarily, difficult to achieve. It is most likely to be
4 achieved when the ventilation and engineering controls are specially designed and/or
5 integrated into the equipment, expertly commissioned and tested regularly to prove it
6 continues to operate at the intended high level of performance.

7 LEV around 90% effectiveness is associated with good design, although possibly
8 employing retro-fitted equipment, good adjustment, and with routine examination and
9 testing to ensure it delivers the required performance and continues to do so.

10 Levels of effectiveness at 80% to 90% are associated with retro-fitted equipment that
11 has not necessarily been fully integrated into the plant. It may allow operators to alter
12 the positioning of hoods or in other ways change the optimal effectiveness of the
13 equipment.

14 Lower levels of effectiveness of LEV (below 80%) are often associated with poor design,
15 inadequate selection of the composite parts and opportunities for worker interference
16 with the system.

17 As an example, a spray-booth compliant to EN 12215 or EN 13355 is required to have a
18 minimum downdraft air velocity of 0.3 m/s which should ensure a minimum 200 air
19 exchanges per hour. This should deliver a 95 % reduction with a well-designed LEV. A
20 spray-stand with efficient exhaust ventilation (0.5 m/s at exhaust screen) ensures 90%
21 reduction. This is an equivalent efficiency to local exhaust ventilation even when it is not
22 literally a local exhaust. It may be reasonable to manually reduce effectiveness values of
23 LEV and engineering controls in the exposure assessment to provide more options during
24 implementation. In this way where high effectiveness is not normal practice, and where
25 the risk characterisation allows, the registrant can propose options that allow use of less
26 sophisticated equipment than would be required, for instance, to otherwise achieve 90%
27 reduction.

28 The effectiveness of the ventilation has a major influence on the predicted exposure.
29 Default effectiveness values for LEV are incorporated into certain Tier 1 modelling tools.
30 Registrants should as far as possible ensure that the effectiveness values they rely on in
31 their assessment align with the type of ventilation arrangements foreseen at typical
32 workplaces.

33 Some limited work has been carried out investigating effectiveness of LEV. A paper
34 published in 2008, investigated published efficacy of RMMs and identified substantial
35 variation, the reasons for which are however not always fully clear [11]. General
36 ventilation arrangements may be a valid exposure modifying factor in some instances
37 where there are uncontained releases to the general workplace environment. However,
38 in cases where the operator is close to the source of emission, general ventilation may
39 have very unpredictable impact and should be considered carefully as a means to further
40 reduce exposure estimates when local exhaust ventilation is already selected as a risk
41 management option.

42 **R.14.5.2.3 Management controls**

43 Management and administrative arrangements can also deliver reduced exposure.

44 It is generally assumed, that good occupational hygiene practice is implemented on site⁸.

⁸ Principles for good occupational hygiene practice can be found in different OHS publications, see for example the UK COSHH *Approved Code of Practice and guidance* (pages 30 to 33) that provides 8 generic principles to be followed as good occupational hygiene practice [42].

1 Nevertheless different levels and opportunities of management controls can be
2 incorporated into the exposure scenario leading also to differences in the risk
3 management effectiveness and hence the expected exposure levels. For example, in
4 ECETOC TRA or MEASE a distinction is made between "industrial" and "professional"
5 setting, which impacts on the i) basic exposure estimate for the single process category
6 and ii) on the expected effectiveness of local exhaust ventilation. Together, the
7 assumption on the "setting" may impact on the exposure estimate by an order of
8 magnitude. In practice, the "industrial" setting means: advanced system to instruct,
9 train and supervise workers; and proper installation, operation, maintenance and
10 cleaning of equipment; and regular cleaning of rooms. (See also *Chapter R.12 of the*
11 *Guidance on IR&CSA* [9])

12 Also, limiting the duration of an activity during the typical 8-hour working day to a
13 shorter period may result in a lower exposure due to that activity. Some Tier 1 exposure
14 estimation tools include an exposure modifier based on duration of the single task.
15 Please note: If limiting the time is a pre-requisite for demonstrating control of risk for a
16 particular contributing scenario, this may have an impact on the work organisation of the
17 downstream user. It may mean that workers should not be exposed to the substance
18 during the remainder of the shift to guarantee safe use. Under OHS legislation, an
19 employer must assess the risk over the entire shift. The registrant may want to include
20 suitable information that supports this need in the exposure scenario for communication.
21 For instance, the risk characterisation ratios may be useful information and could be
22 provided in section 3 of the exposure scenario. In general exposure estimates should not
23 be reduced by applying unlikely time constraints that are not realistic for the expected
24 conditions of use.

25 A further option for exposure reduction may be ensuring workers are remote from the
26 process. Some models can provide refined exposure predictions based on this modifier
27 and real data often reflects the proximity of the worker to the source of exposure
28 throughout the working day.

29

30 **R.14.5.3 Personal protective equipment**

31 Personal protective equipment (PPE) is used when residual exposure cannot be avoided
32 after application of other means. Thus, exposure scenarios that rely on PPE as a primary
33 risk management option should be avoided whenever possible.

34 Selection and use of personal protective equipment will always need to be seen within
35 the context of national OHS legislation where the full range of risks need to be
36 considered. For example, the registrant may need to consider the additional
37 physiological burden introduced by the use of PPE, such as heat stress, or impact on the
38 hands due to long wearing of PPE, if appropriate breaks are not taken.

39 It is the responsibility of the employer to ensure such risks are avoided. This may be
40 particularly relevant to exposures for extended periods, for example when wearing of
41 impervious gloves national legislation requires that breaks are taken to avoid the effect
42 of wet working (e.g. time for continuous wearing of the gloves may need to be limited
43 e.g. 2 hours, 4 hours depending on the case).

44 For the risk characterisation, the RCR should be calculated including the reduction factor
45 achieved by the use of the PPE. The reduction factors applied should be transparently
46 reported in the CSR. Justification should be provided when PPE is specified within
47 exposure scenarios as the primary method to achieve acceptable exposures. One such
48 example is during professional car respraying operations, where RPE and protective
49 clothing are a primary RMM. The use of respiratory protective equipment (RPE) should
50 usually be a temporary measure, during short time intervals, until other technical
51 measures are provided to ensure safe use. RPE should be proposed for use well within its
52 designed performance. This may mean an exposure assessment that indicates a

1 performance of 90% but additional good practice advice may suggest equipment
2 providing 95% or better performance is preferred to meet the requirement of other
3 legislation, especially in cases where the exposures are close to the limit values.

4 PPE to protect against dermal exposure will often be needed due to the very variable and
5 unpredictable nature of dermal exposure. The outcome of the quantitative assessment
6 alone should not be the only information used to propose suitable and adequate gloves
7 and clothing. Glove effectiveness is determined by the management systems in place to
8 ensure the prescribed level of performance. The required level of management is
9 described by the ESCOM phrases ([http://www.cefic.org/Industry-support/Implementing-
10 reach/escom/](http://www.cefic.org/Industry-support/Implementing-reach/escom/)) which are generally included in the exposure scenarios.

11 Gloves alone will not provide protection when other parts of the body are exposed.

12 It is an absolute requirement that the barrier properties of the glove material are known
13 to be adequate to ensure the substance does not migrate through the material of the
14 glove during the proposed use. It is important that gloves are sufficiently described in
15 the IUCLID dossier and the CSR so that there is assurance that suppliers of substances
16 and formulations, can effectively communicate (in section 8 of the Safety Data Sheet)
17 the correct information to downstream users. Important information on gloves relates to
18 those materials that are effective and over what duration they are effective. It is also
19 useful to provide information on common glove materials that are known not to be
20 effective as a barrier.

21 Note: Glove manufacturers' literature may provide indicative information but the best
22 information derives from specific testing against the registered substance. Such
23 information will also help producers of mixtures to select appropriate gloves for their
24 products. Information such as "suitable chemical resistant gloves tested according to EN
25 374" alone does not give sufficiently concrete information to ensure the correct
26 information is available to control the risk adequately down the supply chain.

27 **R.14.5.4 Specific Worker Exposure Descriptions (SWEDs)**

28 When registrants assess the exposure of downstream users further down the supply
29 chain, they often do not have direct access to information on the condition of use and its
30 variety within/across sectors. This is in particular true for uses of mixtures and articles
31 into which the substance has been incorporated somewhere in the supply chain. Thus for
32 registrants under REACH it is a challenge to i) base their assessment on realistic
33 conditions of use and to generate sufficiently reliable exposure estimates (and hence risk
34 characterisation) and ii) to provide practically helpful and use-specific safety advice to
35 customers.

36 To address this challenge, some downstream user sector organisations map out the
37 typical uses and describe the conditions of use in a way that registrants can feed into
38 their CSAs; these are called "use maps". Use maps are developed using a template and
39 describe the typical uses within sectors. They include the description of use and its
40 contributing activities as well as the references to the corresponding inputs to the
41 exposure assessment of workers, environment or consumers⁹.

42 The conditions relating to worker exposure are provided in *specific worker exposure
43 descriptions* (SWEDs), in the form of input values to the assessment tools used at
44 registrant's level. The SWEDs are linked to the corresponding uses/activities from the
45 relevant use maps.

⁹ See also Part D of the Guidance on IR & CSA, Use Maps can be accessed at [http://echa.europa.eu/csr-es-
roadmap/use-maps](http://echa.europa.eu/csr-es-roadmap/use-maps)

1 SWEDs provide conditions of use to be used by registrants as input to the assessment of
2 worker exposure in the CSA. The RMMs are linked to current occupational health and
3 safety guidance when appropriate.

4 Registrants are encouraged to base their assessments on use maps and SWEDs where
5 possible, to ensure that the assessments undertaken are realistic and relevant and the
6 exposure scenarios communicated to downstream users provide useful information to
7 promote the safe use of the substance. Use maps and SWEDs are a development of
8 generic exposure scenario (GES) that were introduced in 2009.

9 **R.14.6 Exposure estimation**

10 **R.14.6.1 Introduction**

11

12 Clearly there are options for registrants to address the exposure assessment
13 requirement by different means, such as modelled estimates of exposure levels,
14 measured representative exposure data for the assessed substance, or monitoring data
15 from substance with analogous use, exposure pattern or analogous properties. When
16 representative exposure data adequately measured are available special consideration
17 shall be given to them, as they may best reflect the real life exposure situation.

18 In many cases it may be appropriate to use a Tier 1 modelling approach to support the
19 REACH registrant's generic assessment for the different uses identified. In other cases
20 however there may be a greater need for reliance on higher tier modelling or appropriate
21 data from measurements. In some cases, a combination of measured data and
22 modelling approaches may lead to the most appropriate assessment.

23 A pragmatic work flow is to start with Tier-1 modelling and, on the basis of the results,
24 to identify a limited number of (contributing) scenarios for which either higher tier
25 modelling or a measurement campaign is needed.

26 Most importantly, the exposure estimate has to be adequate for the purpose of
27 establishing safe use and align with the anticipated real life situation described within the
28 final exposure scenario. The exposure estimates are required to cover all the described
29 uses and take account of the variability within and between tasks, and for users and
30 sites. Where a worker carries out different tasks with the substance over a shift, the
31 exposure resulting from the individual contributing scenarios will add up to a total
32 exposure. In a generic assessment, control of risk should in general be demonstrated for
33 a duration of 8h per task, to make the registrant's safety assessment independent of the
34 work organisation downstream. Where a registrant however chooses to limit the duration
35 of a task to reduce the estimated exposure concentration, he should make the DUs
36 aware of the potential consequence: exposure to the substance during the rest of the
37 shift may need to be avoided (see also section R.14.5.2.3).

38 In the context of application for authorisation, an estimate for the full shift cumulative
39 exposure from the different tasks with the substance should be provided.

40 The exposure estimates should aim to be conservative and reliably cover the conditions
41 described in the exposure scenario; the level of detail required may be limited, but it still
42 needs to be clear which exposures are within scope of that assessment. More refined
43 estimates will include additional information to allow revision of the exposure
44 assessment.

45 Uncertainty of the exposure estimate needs to be considered to ensure that the
46 conditions of use are sufficiently covered by the exposure estimate. Depending on the
47 level of uncertainty around the various factors contributing to the exposure estimate and
48 resulting RCR, it is recommended to refine (re-iterate) the exposure by alternative
49 means, to reduce the uncertainty. This may include for example modelled exposure from

1 higher tier models, sensitivity considerations regarding input data in models, and by
 2 inclusion of or resorting to (additional) measurement data in a weight of evidence
 3 approach to increase reliability of the outcome and to guarantee safe use. Please note: A
 4 risk characterisation ratio close to 1 may clearly indicate the need for such
 5 considerations, especially if the substance has particularly hazardous properties (or is
 6 very potent) and/or if the exposure estimates are not obviously conservative. In order to
 7 support the interpretation of the risk characterisation, the registrant should include in his
 8 CSR a reflection on the uncertainties around his assessment, and how they are dealt
 9 with (see also section 5.4 of *Part D of the Guidance on IR&CSA* [12]).

10 **R.14.6.2 .Assessment of data and information quality**

11 The confidence in a modelled or measured exposure estimate in the context of exposure
 12 assessment and risk characterisation under REACH depends on various considerations.
 13 For exposure estimates based on **measured** data, the confidence increases when:

- 14 • the exposure data has been collected and analysed according to recognised
 15 protocols;
- 16 • the data has been collected as personal exposure, or is directly related to it (e.g.
 17 representative static samples);
- 18 • appropriate information on the conditions of use is available;
- 19 • the number of data points is adequate (see Section R.14.6.4)

20 For exposure estimates based on **modelled** data, the confidence increases when:

- 21 • The model is well documented and tested against independent measured
 22 datasets;
- 23 • one or more peer-reviewed scientific publication is available

24 For both, measured and modelled data, the relationship between i) the actual conditions
 25 of use of the substance and ii) the substance/conditions to which the data source refers
 26 is also important, as shown in Table R.14- 1.

27 Where the source of the modelled or measured exposure estimates deviates from the
 28 general quality requirements, the data can still be used but a particular justification is
 29 needed in the CSR. Potentially a confirmation by other supportive exposure estimates
 30 could increase the confidence.

31 **Table R.14- 1 Implications of the chosen information source**

Data Source	Suitability of data source
MEASURED DATA	
Measured dataset for the substance used/generated for exposure scenario describing the conditions of use at a specific site or a range of very similar sites	Provides sufficient confidence, which is in particular needed when demonstrating safe use for highly hazardous substances not handled in a closed system. For establishing the similarity between sites the variability/distribution of the exposure estimates need to be analysed.

Data Source	Suitability of data source
Measured dataset for substance and/or uses and/or use conditions analogous to the substance/use to be assessed	Particular and detailed justification needed in the CSR regarding the similarity of substance properties and conditions of use. For establishing the similarity the variability/distribution of the exposure estimates need to be analysed.
Measured dataset with partial information only on context (use and conditions of use) and/or origin of data and/or method of sampling and analysis	Usually not suitable for an assessment under REACH. May, however, provide supportive evidence based on a detailed explanation why the data are interpretable despite the missing information.
MODELLED DATA	
Modelled dataset; input parameters match 1:1 with use and use conditions in the exposure scenario; model used in its applicability domain	Assessment can be based on a simple reference to the tool (including its version).
Modelled dataset; actual use/conditions of use need to be "translated" into input parameters; model used within its applicability domain;	Describe the use, independent of how the model/tool input parameters are expressed. Provide an argumentation how the suitable model/tool inputs have been chosen to properly reflect reality (i.e. the actual conditions of use). Potentially confirm by measured data, in particular when risk characterisation is close to 1 and/or substance is highly hazardous.
Assessment case outside the applicability domain of the model (substance properties, input parameters available)	Should be used as supportive evidence only. Provide a robust argumentation why nevertheless the exposure estimate is relevant in context of the assessment case.

1 **R.14.6.3 Use of measured data**

- 2 REACH does not require that registrants use measured data for the purpose of exposure
 3 assessment or that, if they are used, they are generated for that purpose. Thus, the
 4 measured data have often been generated for other purposes. If relevant data do exist,
 5 they should be interpreted as part of the exposure assessment reported within the CSR.
 6 Where no specific data exist, appropriate analogous data from similar conditions of use
 7 could be used.
- 8 As already mentioned in Section R.14.4.4, the purpose of the exposure assessment in
 9 the CSR for registration is the description of conditions under which safe use is possible
 10 (exposure scenario). It is not the purpose to describe conditions covering companies

1 with no or insufficient exposure controls. Based on this, the exposure estimates should
2 be consistent and representative for the safe use conditions described and thus existing
3 data from measurements aiming to identify unsafe conditions of use or (too) high
4 exposure may not be suitable for a registration under REACH

5 Sources of measured data that may be useful in the context of REACH are:

- 6 • measured data taken under the actual exposure settings for the (contributing)
7 exposure scenario to be developed. For example, data generated to comply with
8 other legislation or to evaluate the effectiveness of the RMMs in place;
- 9 • exposure information from databases if information requirements enabling a
10 robust assessment are fulfilled;
- 11 • biomonitoring data.(see section R.14.6.4.4)

12 Workplace exposure data have a key role in the assessment of individual workplaces to
13 help fulfil the provisions of the Chemical Agents Directive (98/24/EC) and in evaluating
14 the effectiveness of the RMM in place and thus it can be assumed that exposure
15 estimates for many workplaces exist already.

16 Exposure data is typically obtained from personal samples. Static samples may also be
17 valid if they reflect the personal exposure and provide a conservative estimate for it.

18 For registrants, however, the data may not always be easily interpreted in the context
19 of the final exposure scenario required by REACH. Under REACH, registrants may not
20 have access to the measured exposure data from downstream users and are even less
21 likely to have access to the full documentation related to the exposure estimates (e.g.
22 data from individual measurements, OC/RMM of these data etc.).

23 There may be cases where information sources include reliable documentation of
24 workplace measurements (databases), such as that collected by manufacturers,
25 downstream users or sector organisations, to help fulfil the provisions of the Chemical
26 Agents Directive (98/24/EC), the Carcinogens and Mutagens Directive (2004/37/EC) or
27 for research purposes. Such data, if of a suitable quality and supported by sufficient
28 information, may provide good evidence. A professional judgement needs to be made on
29 the relevance and representativeness and to decide if the data correspond to the
30 conditions of use described in the final exposure scenario and can therefore be used as a
31 exposure estimate and /or to supplement modelled estimates.

32 **R.14.6.3.1 Representativeness of the data and variability of exposure**

33 Available exposure data, even in well-defined situations, have substantial variability.
34 Additionally, the exposure data are associated with certain OCs and RMMs. Both, the
35 exposure distribution and the representativeness of the data to the exposure settings to
36 be assessed need to be taken into account.

37 A key requirement for the final outcome of an assessment is to be representative of the
38 (contributing) scenario to be assessed. For instance, the RMMs prevailing during
39 sampling (i.e. the generation of the measured data), should be similar (provide at least
40 the same efficiency) as the ones reflected in the (C)ES. The representativeness of the
41 data is further discussed in Section R.14.6.4.1.

42
43
44 Variability of measured data is reflected by the spread of the distribution of the individual
45 exposure data points. This variability may be introduced through a number of factors.
46 These factors include differences in application of operational conditions, level of
47 (substance) throughput, other local conditions, variability in performance of RMMs s,
48 (lack of) maintenance of plant over time, and behavioural differences between workers.

1 Exposure distributions can be reasonably described by the geometric mean (GM) and the
2 geometric standard deviation (GSD). Whereas the GM is an estimate of the central
3 tendency of the distribution, the GSD can be used as an indicator for the spread of the
4 distribution (i.e. for the level of variability). Percentiles (e.g. 75th, 90th) show the
5 percentage of the measured exposure levels that are at or below a certain value (e.g.
6 the 90th percentile value indicates that 90% of the measured exposure levels are at or
7 below that value). In general the 90th percentile value, representing the reasonable
8 worst case exposure level of a distribution within a generally suitable dataset (i.e. a
9 dataset corresponding to the conditions described in a contributing scenario), should be
10 used as the exposure value for the risk characterisation. Under particular conditions
11 other percentiles may be applicable as well. A justification should be provided in the
12 CSR. For instance, the use of the 75th percentile may be justified when the data set
13 reflects worst case situation only (e.g. data sets taken in companies suspected of being
14 non-compliant).

15 High (e.g. maximum) values of a data set are part of the exposure distribution and,
16 unless there is a reason to reject them, should remain in the distribution to help in
17 defining that distribution. An assessor may judge that very high values are so far out of
18 scope and caused by factors that are not possibly associated with the exposure scenario
19 (not reasonably foreseeable or may represent sampling artefacts) that they may be
20 removed, but only on that basis and with a sound justification.

21 Measurements below the detection limit are in principle also part of the exposure
22 distribution. However, how to include them could be challenging. Accepted practice
23 includes using the limit of detection (or fraction of it) to calculate the concentration to be
24 included in the distribution or the use of more sophisticated tools (see for instance Excel
25 tool Implementing the BOHS/NVvA Sampling Strategy¹⁰
26 <http://www.bsoh.be/?q=en/node/67>)¹¹. The procedure that has been used to take
27 account of non-detects in the statistical analysis of a data set should be clearly described
28 in the CSR.

29 **R.14.6.3.2 Analogous data**

30 When appropriate representative measured data for the registered substance are not
31 available, an alternative is the use of measured data for analogous substances, that are
32 used in the same way as the assessed substance, or from the assessed substance, that
33 is used in analogous situations. Analogous substances should have close enough
34 physico-chemical properties to the registered substance and be used in a similar enough
35 way. In some cases, it may be possible to use measurement data for the substance
36 taken from analogous situations. For example, with justification, gluing instead of
37 painting may be a similar enough task in some cases given that other conditions of use
38 are comparable as well. Justification needs to be provided to support an exposure
39 assessment based on analogous data.

40 When using data from analogous substances, the registrant must justify that estimations
41 provide an appropriately conservative outcome. For instance, an estimation based on
42 data from a more volatile substance is on the safe side, while an estimation based on
43 data from a less volatile substance is not on the safe side, and it may lead to an
44 underestimation of risk. For example, using toluene data to support estimates for xylene
45 may be possible if OCs and RMMs are similar. Toluene has a lower boiling point and
46 higher vapour pressure than xylene with the expectation that exposure would be higher

¹⁰The BOHS/NVvA Sampling Strategy implemented in the excel tool is available at:
<http://www.arbeidshygiene.nl/-uploads/files/insite/2011-12-bohs-nvva-sampling-strategy-guidance.pdf>

1 under the same conditions of use. However, the estimation of toluene exposure based on
2 xylene exposure may not be equally appropriate, as toluene is more volatile. Volatility is
3 an important parameter for inhalation exposure and comparability should be justified.
4 However, care needs to be taken to ensure that the conditions of use are similar as
5 some substances of higher volatility may be used in a more controlled way, possibly due
6 to concerns over flammability, odour or toxicity.

7 **R.14.6.4 Selection and interpretation of measured data**

8 **R.14.6.4.1 General aspects**

9 The purpose for which data were collected needs to be taken into account when
10 considering the representativeness of the data (and thus, it affects whether and how the
11 data can be used in a REACH exposure assessment). Data sources need to be assessed
12 carefully for relevance for the assessment to be done. For instance, data may have been
13 collected for compliance purposes or to demonstrate good practice. They may also have
14 been collected at a time when the OELs were higher and improvements in the working
15 conditions could have been implemented since. The data may also be representative of
16 worker exposure where the individual is involved in a number of tasks in a day and
17 include periods where there is no activity. In the case of the assessment of a single site
18 (e.g. registrant's own site), the use of measurements is simpler. In this case, the data
19 are representative of the OC and RMM available in the company and the assessor will
20 most likely have access to all the documentation related to the sampling.

21 When assessing a broader situation (for instance across a sector), care should be taken
22 that the data are representative. Issues to be assessed include:

- 23 • The data set should be representative of the OC and RMM described in the
24 exposure scenario. This is a basic condition for acceptance of the data. The
25 similarity in tasks, the technology (e.g. level of automation), scale of the
26 processes (gluing small parts is quite different from gluing flooring in buildings)
27 and the potential variation this introduces needs to be considered.
- 28 • In order to be applicable to a sector, the data set should represent the typical
29 conditions within the sector suitable to assure safe use. The tasks (or combination
30 of tasks) that the data set represents should be made clear. The downstream
31 user should be able to judge whether the data set is applicable for their own work
32 arrangements (e.g. differences on frequency of tasks).

33

34 In a regulatory context, for substances of low concern, provision of reasonably
35 foreseeable worst case exposure data may allow a simple assessment of risk to establish
36 safe use.

37 Generally, there needs to be enough information to satisfactorily support the suitability
38 and representativeness. Indicators of good quality data in this context are:

- 39 • reference to quality schemes and standard sampling and measurement
40 methodologies;
- 41 • sufficient description to support the intended scope;
- 42 • clear description of monitored tasks;
- 43 • clear information on RMMs in operation during sampling;
- 44 • details of duration and frequency of tasks as well as an assessment if the
45 sampling duration is representative of full-shift exposure or only for the task
46 duration;
- 47 • data collected using static samplers should only be used in the exposure
48 estimation if there is sufficient information provided to demonstrate how they

1 reflect personal exposures or that they provide a conservative estimate of
2 personal exposures (i.e. that in this situation personal exposure levels would be
3 lower than results from static samples). Air samples should be taken at breathing
4 zone height and in the immediate vicinity of workers. If there is a large quantity
5 of pooled and statistically evaluated data available, these data may be used
6 provided that the methods used to do this and reasons for using data from static
7 sampling are made clear.

- 8
- 9 • whether data are current rather than historical (i.e. sampling period to be
10 reported);
 - 11 • collection from a wide range of the sites and processes covered by the use
12 description;
 - 13 • Individual values (data points) and/or statistical descriptors available.

14 The CSR should contain sufficient information for the reader to understand the decision
15 making. For instance, in many cases, the single data points will not need to be reported
16 and the statistical parameters characterising the distribution would be sufficient.
17 However, if some data points had been removed from the data set (e.g. maximum
18 values), the reader may need more information to be able to judge whether that was
19 adequate.

20 **R.14.6.4.2 Inhalation data and sample size**

21 Inhalation exposure data to be used in occupational exposure assessments under REACH
22 should relate to concentration of the substance in the breathing zone of the operator and
23 before any respiratory protection is factored into the assessment. The concentration
24 measured, time-weighted if appropriate, is compared with the appropriate DNEL.

25 Inhalation exposure data tend to be log-normally distributed. For regulatory decision-
26 making, enough data are required to establish the key values from the distribution.

27 The confidence in the estimated exposure value, for regulatory purposes, generally
28 increases with sample size, as long as the data truly represent the full variability across
29 industry. This can only be assessed through good quality supporting information
30 associated with the data set.

31 The number of data points required will differ depending on whether the ES is intended
32 to cover a single company (e.g. assessment of its own site) or a broader situation (e.g.
33 in a top-down assessment).

34 Guidelines on sampling strategy are available from many sources including the European
35 Committee for Standardization (CEN). European national organizations have also
36 publications on sampling strategy¹².

37 These publications provide advice that is in some cases directly applicable in a REACH
38 context. For instance, how to calculate a TWA will follow the same mechanism (but
39 within REACH it usually would refer to a task and not a full-shift) and the same
40 considerations are applicable to the adequate duration of the sampling within REACH and
41 OHS. Other aspects such as number of data points required for an adequate assessment
42 would need adaptation

¹² See for instance the list of references/ Links for further reading in the EU-OSHA wiki page dedicated to
sampling of airborne chemicals
https://oshwiki.eu/wiki/Monitoring,_sampling_and_analysis_of_airborne_dangerous_substances#Sampling_strategy

1 For example, for the assessment of a single company, the European Standard EN 689
2 [13] (currently under revision) provides recommendations on how to choose the
3 adequate number of workers for exposure measurements, which will vary depending on
4 the strategy chosen (e.g. random sampling, use of homogeneous exposure groups etc.).
5 As a possible approach, the standard recommends that at least 6 data points should be
6 presented to adequately describe the exposure of a single work activity within one
7 company. In this case, narrow distributions are expected (and required by the standard)
8 as the sampling is based on homogeneous exposure groups, i.e. on a group of workers
9 performing identical or similar task and that are expected to have similar exposure levels
10 to the same substance.

11 On the other hand, assessing exposure for broad exposure situations needs more data to
12 ensure sufficient coverage of the broad situation and to enable evaluation of potentially
13 relevant subsets (for instance higher exposure situations). In this type of assessment,
14 narrow distributions may indicate not all independent variables have been accounted for,
15 such as the full range of activities and between worker or between site variability.

16 Another important factor is the quotient between the exposure level and the DNEL
17 involved, called the RCR (risk characterisation ratio).

18 As explained in *Chapter R.19 of the IR&CSA guidance* [14] each step of the risk
19 assessment process, including the exposure estimation has an associated uncertainty. In
20 order to have a robust CS, the registrant needs to consider whether these sources of
21 uncertainty are adequately addressed and provide enough confidence in the calculated
22 RCR. Thus, when the RCR is close to 1, taking into account the uncertainty associated
23 with the measured data is of high importance. This usually involves a critical
24 consideration of the representativeness of the data and an increased amount of
25 measurement data points to verify that the DNEL will not be exceeded.

26 Regarding the assessment of one single site, various sampling protocols provide advice
27 on this matter giving clear recommendations based on the RCR and the variability of the
28 data (as GSD). These include for instance the standard EN 689¹³.

29 For broader assessments, the number of data points needed to ensure that the data are
30 robust enough to provide sufficient confidence that exposure is below the DNEL should
31 be decided on the following principles:

- 32 • data from one company is unlikely to be representative of a whole industrial
33 sector consisting of multiple sites;
- 34 • A higher number of data points is required:
 - 35 ○ the closer the RCR is to 1;
 - 36 ○ with higher variability of the data (represented by the geometric standard
37 deviation of the exposure distribution);
 - 38 ○ if the representativeness of the data are suspected to be significantly
39 uncertain for the situation to be assessed.

40 In order to obtain representative inhalation exposure measurements the duration and
41 time of the monitoring should be carefully chosen.

¹³ Other relevant document on sampling strategy is the BOHS/NVVA guidance <http://www.arbeidshygiene.nl/uploads/files/insite/2011-12-bohs-nvva-sampling-strategy-guidance.pdf>

1 **R.14.6.4.3 Dermal data**

2 Dermal exposure data are rarely available and often difficult to interpret, because of
3 missing contextual information and/or information on the measurement method. Some
4 sectors are working to generate specific data sets based on agreed sampling protocols to
5 address their needs. In most cases, the default approach in assessing dermal exposure
6 should be to seek to use exposure models and particularly those that have been
7 validated by publications and are based on, or benchmarked against, real data. Dermal
8 exposure assessment has large uncertainty associated with it and results should be
9 considered in that context.

10 Measured dermal data may be available for some analogous situations. Most often, these
11 data reflect uses such as uses for biocides and plant protection products. With
12 professional judgement, these data can be used to address similar situations for REACH
13 registered substances. It is clear, in the case of dermal exposure data, that they may not
14 adequately describe REACH compliant conditions as often they will have been collected
15 without standard industrial controls in place. It could represent the wrong exposure
16 distribution and lead to either under-prediction or over-prediction of exposure. Some
17 tasks are well described by existing generic data, such as spraying and transferring of
18 powders and liquids.

19 Measured dermal exposure data are most often presented as a rate of exposure in
20 mg/min or µl/min of in-use formulation (i.e. allowing the user to take account of
21 concentration of substance in the mixture).

22 In some cases measured dermal exposure data may include information on surface area
23 sampled (cm²) and mass of contaminant depositing (mg), allowing an estimate to be
24 made of mass per unit area (mg/cm²). This is mostly relevant where the exposure is
25 expected to be evenly spread over the skin surface, such as with a specifically applied
26 formulation. Information may also be available on duration of exposure and the
27 frequency.

28 A good source of pre-existing data is the RISKOFDERM project. The project resulted in
29 development of an expert model for estimating potential dermal exposure (see Section
30 0). A further resource for dermal exposure data (which includes all the Riskofderm raw
31 data) is the BEAT model (see Section A.14-1.4.3), originally developed for assessment of
32 biocidal products. The data within that model are presented generically but the
33 scenarios are mainly directly relevant to biocidal uses, however these data may still be
34 used to help address some REACH-relevant exposure scenarios; for example, dermal
35 exposure arising from professional spray painting. The raw BEAT data (over 1400
36 exposure estimates, including all RISKOFDERM data) can be fully accessed via the model
37 but requires expert interpretation (see ECHA Guidance¹⁴).

38 **R.14.6.4.4 Biological monitoring data**

39 Biological monitoring may be employed as an exposure monitoring tool to help evaluate
40 the effectiveness of risk management measures – exceedances of benchmark values
41 prompting investigation into the causes of loss of control in the workplace. When
42 available, biological monitoring data may be usable within exposure assessment but
43 interpretation is often difficult in the context of comparison with DNELs. It generates
44 results that may be compared with biological monitoring guidance values (BMGVs) or

¹⁴ Guidance on the BPR: Volume III Human Health, Part B Assessment (Chapter 3 Exposure assessment)
[<http://echa.europa.eu/web/guest/guidance-documents/guidance-on-biocides-legislation>]

Biocides Human Health Exposure Methodology Document [<http://echa.europa.eu/about-us/who-we-are/biocidal-products-committee/working-groups/human-exposure>]

1 workplace biological monitoring exposure standards. It can add value to the exposure
2 assessment process by providing information that enables a better understanding of the
3 nature and extent of the total exposure through all exposure routes. Most biological
4 monitoring metrics cannot easily be compared to daily systemic dose for comparison
5 with a DNEL as they relate to a concentration in the collected fluids (generally urine), but
6 it may, for instance, demonstrate uptake is very low for specified tasks. It may allow
7 tasks to be ranked in terms of their potential to cause exposure.

8 For some substances biological monitoring methods already exist. New methods may
9 require a lengthy development phase and though achievable in principle, in practice, few
10 new methods will be developed.

11 Biological monitoring results reflect total exposure to the substance through any relevant
12 route and from any source, i.e. from consumer exposure, man via environment in
13 addition to occupational exposure through inhalation, dermal absorption and ingestion.
14 In the case of confounding variables it may be difficult to link biological monitoring data
15 to specific exposure scenarios, even though in many cases occupational exposure is the
16 most significant. In cases where there is an identified exposure from other sources (e.g.
17 water, food) biomonitoring can act as a useful means to identify potential for
18 occupational exposure to cause exceedance of any pre-existing limits.

19 Biological monitoring data need to be seen within context. Information should be
20 provided on which metabolite is measured, the sampling strategy, the biological half-life
21 of the metabolite and how to interpret the results against pre-defined standards. Where
22 reference is made to pre-defined standards, the basis for the standard should be clearly
23 described. Aspects to address may include whether the standard has any implications for
24 health or is intended to act as a good practice benchmark, whether the marker is found
25 in unexposed populations, and any confounding exposures have been identified.
26 Biological monitoring data should be presented with the same core information as data
27 on inhalation or dermal exposure to enable proper interpretation of the outcome in
28 relation to working conditions.

29 In order to make best use of biological monitoring data, it is necessary to compare
30 measured data against an appropriate standard. The toxicokinetic properties (e.g.
31 absorption percentages) that form the basis for any relationship between the biomarker
32 and external dose metrics should be clearly described. The comparison of biomonitoring
33 data with DNELs is further described in *Chapter R.8 of the IR&CSA Guidance* [1].

34 **R.14.6.5 Assessment of acute exposures**

35 Exposure to some substances may lead to acute health effects. The assessment of acute
36 exposures becomes necessary when either an acute DNEL or a DNEL for acute local
37 effects have been derived.

38 For highly toxic substances that can produce serious effects after a very short exposure
39 time (i.e. a few seconds), strictly controlled conditions would normally apply. System
40 breaks (e.g. system leaks or loss of containment) will be treated as an accidental release
41 and thus, short-term qualitative exposure assessment is not expected.

42 **R.14.6.5.1 Assessment of acute inhalation exposure**

43 Assessment of short-term (acute) inhalation exposure is required when an inhalation
44 DNEL has been derived for acute effects. It is also relevant when the substance
45 produces local effects and the concern is that knowledge of short intense exposure is at
46 least as important as longer term exposures.

47 Short-term inhalation exposure is normally estimated over a 15-minute reference period
48 (but shorter periods may be applicable depending on the effect). The short-term
49 exposure profile may determine the risk management measures. For example, consider
50 a limited-period high exposure solvent application task in a printing works that is carried

1 out for only 15 minutes in a day. The predicted exposure for the 15 minutes of the task
2 may be many times higher than the predicted 8-hour time-weighted average for the
3 whole shift, and specific risk management measures will need to be determined for that
4 task.

5 Care should be taken when estimating the exposure. Most of the exposure modelling
6 tools (see outputs for the tools in Section R.14.6.6) do not address the assessment of
7 short-term exposures. In those cases, the exposure cannot be estimated by using the
8 tool and choosing the option "less than 15 minutes" (or similar) for exposure duration;
9 this is because the duration is not meant to address acute exposure but an activity that
10 is performed less than 15 min per day (i.e. the concentration given by the tool is
11 averaged for 8 hours instead of 15 min and is meant to be compared with a chronic
12 DNEL).

13 The short-term exposure **can be modelled** by using the Advance REACH Tool (ART) or
14 Stoffenmanager (see Sections A.14-1.4.4 and A.14-1.4.1) or by extrapolation from the
15 long-term exposure under certain conditions.

16 If the activity assessed is considered to lead to stable exposure levels (without any task
17 leading to exposure peaks) extrapolation from the measured or modelled long-term
18 exposure can be used consisting of a multiplier of the 8 hours exposure estimate for the
19 task (ECETOC TRA uses a factor of 4).

20 If peaks of exposure are expected due to the nature of the activity (for example, opening
21 vessels etc.), the extrapolation from the average shift exposure cannot be used. In such
22 cases the exposure needs to be estimated by other means, for example, by using a tool
23 like ART or Stoffenmanager that allows this type of assessment or by using
24 measurements.

25 When using measurements, sampling strategy for acute exposures can be found in
26 general occupational hygiene guidelines and it generally covers two options:

- 27 • If the higher exposure activities can be identified, measurements will be taken
28 around these activities (in general 15 minute samples, or direct reading devices
29 measurements)
- 30 • If the higher exposure activities cannot be identified a more complicated strategy
31 is needed (for example, a screening step to know the exposure pattern or taking
32 15 minute samples randomly during the whole task)

33 Measurement methods are usually similar for acute tasks but care needs to be taken to
34 ensure the methods are accurate enough and provide an adequate limit of detection (see
35 section R.14.2.1 for more information for requirements for analytical methods for
36 comparison with a limit value).

37 **R.14.6.5.2 Acute dermal exposure assessment**

38 Inhalation and dermal exposure have very different characteristics. The derivation of
39 short-term quantitative exposure estimates for the dermal route may be complex.

40 Exposure estimation for local effects on the skin uses other units (mg/cm^2 or $\mu\text{g}/\text{cm}^2$),
41 which are difficult to assess and is driven to a large extent by the concentration of the
42 assessed substance in the contamination reaching the skin. The exposure associated
43 with the maximum percentage of substance in the product should be used as the basis
44 for managing acute local skin effects. The assumption is that exposure needs to be
45 prevented and a qualitative assessment is most often required to establish the
46 appropriate risk management options leading to a situation where the likelihood of
47 effects is avoided. Ideally, risk management strategies should aim to engineer out
48 opportunities for high acute dermal exposures.

1 **R.14.6.6 Use of exposure estimation tools**

2 The currently available tools for occupational exposure estimation have been developed
3 to be relatively simple to use. The tools are intended to provide appropriately
4 conservative estimates when used correctly.

5 Exposure estimation tools have limitations to their domain of applicability, such as the
6 scope of the intended use or to physico-chemical properties of the substances that may
7 be assessed. Users are required to ensure that the assessment is within published
8 boundaries. Where modelling tools are used for situations outside their applicability
9 domains, the exposure estimates should only be used in the assessment as supporting
10 evidence (It is anticipated that tool outputs reflect the appropriate application of good
11 occupational hygiene practice within the prediction).

12 All tools allow the user to specify some input parameters often including operational
13 conditions and risk management measures, although RMMs may need to be addressed
14 externally to some tools. The inputs should reflect realistic and relevant exposure
15 scenarios. To support this, use maps have been developed by sector organisations that
16 describe typical conditions of use within their sectors and can be readily incorporated by
17 registrants in their chemical safety assessment. Development of non-existent or
18 unrealistic exposure scenarios within a Chemical Safety Report should be avoided and
19 are unhelpful in the context of assessing the scenarios that matter.

20 The TREXMO tool may be a useful source of information on how the different tools define
21 the exposure determinants. The tool establishes a common ground for all models by
22 making the assumption that a set of input parameters in one model can be translated
23 into another model. Further information about the TREXMO tool is available at
24 <https://www.seco.admin.ch/trexmo>.

25 The common tools that are currently available are outlined in Appendix R.14-1, together
26 with the domain of applicability (as claimed by tool owners), inputs and outputs. Newer
27 versions of tools and other tools not included here can be used if appropriate. Referring
28 to the tool owner user guidance is a necessity if they are to be used successfully. A
29 basic overview of the different scope and domains of applicability of the tools based on
30 [15] is given the Table R.14- 2 and Table R.14- 3 below.

1

2 **Table R.14- 2: Applicability matrix (inhalation models)**

Applicability	ECETOC TRA	MEASE	EMKG-EXPO-TOOL	STOFFENMANAGER	ART
PROC codes (as input)	Yes	Yes	No	No	No
Covered physical state	Solid /liquid=volatile	Solid /liquid	Solid /liquid	Solid /liquid	Solid /liquid
Beyond scope	<ul style="list-style-type: none"> •Fibres •aerosol mist •emissions from hot processes (e.g. fumes) •gases •caution needs to be exercised when applying to CMRs and very high hazard substances •solids in liquids 	<ul style="list-style-type: none"> •organic substances •some restrictions concerning special combinations of PROC/physical properties 	<ul style="list-style-type: none"> •Dusts by abrasive techniques, •fumes (soldering, welding, acid fumes) •gases •open spray •pesticides •wood dusts •CMR substances 	<ul style="list-style-type: none"> •Fibres •gases or hot working techniques (welding, soldering, acid fumes) 	<ul style="list-style-type: none"> •Dust resulting from emissions during hot metallurgical processes •fibres •fumes •gases •solutions of solids in liquids
Basis of use description	process based	process based	task based (control guidance sheets)	task based	task based

3

4

5

1
2
3

Table R.14- 3 Applicability matrix (dermal models)

Applicability	ECETOC TRA	MEASE	RISKOFDERM	BEAT
PROC codes (as input)	Yes	Yes	No	No
Covered physical state	solid liquid = volatile	solid liquid	solid liquid	solid liquid
Beyond scope	<ul style="list-style-type: none"> •Fibres •liquid aerosols (if this is dermal – liquid deposition from aerosol is covered e.g. at spraying PROCs 7 and 11.) •or emissions from •hot processes (e.g. •fumes) •caution also needs to be exercised when applying to CMRs 	<ul style="list-style-type: none"> •organic substances 	<ul style="list-style-type: none"> •sometimes restrictions due to original data set ("only on manual tasks for powders") •fumes not covered 	<ul style="list-style-type: none"> •Ultimately, the scope is determined by an understanding of the tool’s capabilities. Unfamiliar situations can be addressed through professional judgement on degree of “likeness” and merging of data sets or inclusion of available real data.
Basis of use description	process based	process based	task based	task based

4
5

1
2 Experience from using the tools, along with increased research aimed at validating the
3 outputs, is an ongoing process.

4 The E-TEAM project evaluated parts of the generic exposure estimation tools for
5 inhalation that are currently widely used for chemical safety assessments under REACH
6 in order to record the applicability domains of the models and to achieve more
7 confidence about the accuracy and reliability of model predictions. The E-Team analyses
8 appear to indicate that overall the tools investigated in the study are suitable for
9 application at Tier 1 of REACH. However, results from the E-TEAM project have been
10 interpreted as showing some tier 1 models may not always produce sufficiently
11 conservative exposure estimates. Furthermore, under the conditions of the study, high
12 levels of variability between users were found. The reports of the project (see [15]) may
13 assist registrants to choose the most appropriate model for a given exposure situation.
14 The E-TEAM analyses have helped identification of elements in these tools that may
15 benefit from review leading to possible revision and ultimately convergence between
16 models.

17 The tools continue to be developed and it is the responsibility of the registrant to ensure
18 the use of an appropriate tool and most recent version of tools are used to predict
19 exposure. It is not the purpose of this guidance to endorse or assess the overall validity
20 of outputs from any of the tools.

21 **Variability and uncertainty in exposure estimation tools**

22 All tools incorporate uncertainties and variability, and models can both over-predict and
23 under-predict.

24 In regulatory exposure assessment, it is important not to erode any conservatism within
25 the tool through application of artificial external mechanisms that modify the outputs.
26 For example, many tools, including ECETOC TRA, employ a banded approach to take
27 account of influence of duration and concentration on the model output. It is generally
28 not admissible to further refine these outputs through, for example, applying linear
29 reductions for elements such as concentration in mixtures or duration of exposure unless
30 robust scientific justification is provided.

31 For similar inputs into various tools, there can be significant differences between the
32 outputs. These differences may reflect the datasets that the model is based on, the
33 algorithms used to predict exposures or the intended purpose. Also, users may interpret
34 the tool-specific inputs differently and there can be differences introduced by
35 experienced and inexperienced users. For these reasons, it is important that registrants
36 provide a justification for the parameters they have used to generate exposure
37 estimates, especially if diverting from tool defaults. Modelling tools should be used only
38 when there is an understanding of the use conditions to be assessed.

39 Tool specific training can help reduce the between-user variability and improve the
40 adequate use of the tools. Moreover, the variability can be further reduced by reviewing
41 the exposure estimates with others (e.g. colleagues).

42 The registrant can help to reduce the uncertainty within risk characterisation by
43 comparing the estimates from a range of sources, including other tools and measured
44 data. Given the uncertainty inherent in many tools, generation of RCRs close to 1 may
45 indicate that further investigation is necessary, such as further iteration within the tool
46 or assessment by other means.

47 Use of single tool estimates is unlikely to be persuasive enough for the purposes of
48 assessing circumstances related to strictly controlled conditions or for proving the low
49 level exposures that may be demanded by authorisation processes under REACH or
50 when justifying exposure based adaptation.

51 A factor that can have a significant impact on the estimated exposure is the selection of

1 the task descriptor (see *Chapter R.12 of the IR&CSA Guidance* [9]). In Tier 1
2 assessments, very often Process Categories (PROCs) are used which are intended to
3 cover the routine tasks carried out under that broad categorisation. These would include
4 elements such as plant adjustments and routine daily cleaning tasks which are part of
5 normal operation but would not be assessed separately.

6 Some forms of exposure assessment are not well addressed and the uncertainty is
7 greater. This is currently the case for inhalation exposure to aerosol droplets , although
8 recent approaches to modelling will allow generation of some estimates (SprayExpo)¹⁵.
9 SprayExpo is able to estimate inhalation exposure and dermal exposure to non-
10 evaporating substances and has been validated with measurement results from real
11 workplaces in the fields of antifouling and stored product protection.

12 The BEAT model (see Section A.14-1.4.3) addresses some tasks where aerosol droplets
13 are released (painting, spraying) and scenarios can sometimes be sufficiently analogous
14 to industrial processes for the data to be useful at a screening level, even though
15 possibly over-predictive for what is the usually more controlled industrial workplace
16 environment.

17 **Dermal Exposure Models**

18 The models can be applied to a range of situations and their outputs used to help screen
19 obviously lower level exposure scenarios. It will rarely be possible for measured data
20 sets to challenge the validity of the generic data based exposure models. The current
21 database models, though still limited in scope, are built around data specifically collected
22 for the purpose of model development and the raw data may be considered analogous.

23 The preferred approach to quantitative assessment of dermal exposure is to use generic
24 database models and to supplement the outputs with real data, but only if they are
25 available. Exposure models such as Riskofderm use a set of database models.

26 Modelling techniques may help to further characterise the potential for systemic uptake
27 following dermal deposition. This is important where there is no indication of absorption
28 being taken account of in the derivation of the DNEL. The IH SkinPerm mathematical
29 tool requires users to input physico-chemical properties of substances and predicts the
30 fate of the substance, after impingement on the skin, through losses to evaporation,
31 residence in the stratum corneum and absorption into the body [16]. Exposure reducing
32 effects due to evaporation cannot be considered if workers have continuous direct
33 contact with the substance. Furthermore, to take the evaporation of a substance into
34 account, non-occlusive dermal exposure has to be the predominant exposure situation.

35

36 **R.14.7 Exposure Assessment and Applications for** 37 **Authorisation**

38 **R.14.7.1 Special requirements of Applications for Authorisation** 39 **(Afa)**

40 The previous sections of this guidance addressed registrants in general, however this
41 section highlights some of the differences in the exposure assessment required in the
42 authorisation process, which potential applicants may take into account when preparing
43 an application for authorisation.

44

¹⁵ <http://www.baua.de/en/Topics-from-A-to-Z/Hazardous-Substances/SprayExpo.html>

1 Under the 'adequate control' route an authorisation shall be granted if it is demonstrated
2 that the risk to human health or the environment from the use of the substance arising
3 from the intrinsic properties specified in Annex XIV is adequately controlled in
4 accordance with section 6.4 of Annex I {Art. 60(2)}, taking into account Article 60(3).
5 While this route may appear rather familiar, the second route for authorisation, the
6 'socio-economic' route, is a fundamentally different approach.
7 Under the socio-economic route an authorisation may be granted if it can be
8 demonstrated that the risk to human health or the environment from the use of the
9 substance is outweighed by the socio-economic benefits, provided there are no suitable
10 alternative substances or technologies. Nevertheless, the appropriateness and
11 effectiveness of the (RMM) will be assessed {Art. 60(4)} as well. Where the Risk
12 Assessment Committee (RAC) will not concur with the claim of the applicant of adequate
13 control in the CSR the application will leave the adequate control route and enter into the
14 socio-economic route.

15 To demonstrate that the socio-economic benefits of the continued use of the substance
16 outweigh the risks to human health (or the environment), an impact assessment must
17 be performed in addition to a risk assessment, e.g. the risks must be evaluated and
18 monetised to quantify the impact on human health or the environment. According to this
19 requirement, in contrast to registration, the derivation of a DMEL is not a useful step, as
20 it would preclude the impact assessment. Instead a dose response relationship may be
21 used to assess the risk and the impact of the continued use of the substance. RAC aims
22 to publish well in advance the dose response relationships to be used in the assessment
23 of applications.

24 [For further information on the Authorisation process and the terminology used, the
25 reader is referred to the ECHA Webpages [[http://echa.europa.eu/applying-for-
26 authorisation](http://echa.europa.eu/applying-for-authorisation)] and the Guidance on the preparation of an application for authorisation
27 (http://echa.europa.eu/documents/10162/13637/authorisation_application_en.pdf).]

28 In the assessment of exposure for registration purposes, the focus is in general on the
29 adequate control of exposure and on the derivation of appropriate Risk Management
30 Measures (RMMs) and Operational Conditions (OCs) which are communicated throughout
31 the supply chain to ensure safe use. In comparison, in the assessment of exposure for
32 an authorisation application, it must be specified which RMMs and OCs have been
33 implemented at all sites of use (e.g. site of manufacture and all downstream user (DU)
34 sites) because the impact assessment is based on the actual implemented RMMs and
35 OCs described in the application.

36 Pursuant to Annex I, 0.8 of REACH, the level of detail required in describing an exposure
37 scenario will vary substantially from case to case, depending on the use of the substance
38 and its hazardous properties. According to Annex I, 5.2.5 of REACH, where adequately
39 measured, representative exposure data are available, special consideration must be
40 given to them when conducting the exposure assessment.

41 Authorisation concerns substances of very high concern, and therefore adequately
42 measured, representative occupational exposure data should be available, and need to
43 be submitted in the application. This requirement is consistent with the requirements
44 under the Chemical Agent Directive (98/24/EC) and Carcinogen and Mutagens Directive
45 (2004/37/EC). For such substances, the exposure scenario needs to be detailed and
46 conclusive.

47 Furthermore, as it is noted in the note on a Common Approach of RAC and SEAC,
48 incomplete or missing information and weak evidence could make RAC and SEAC to
49 advise on more stringent conditions or short review periods in the final opinion. [Ref.:
50 Common Approach of RAC and SEAC in opinion development on applications for
51 authorisations
52 (http://echa.europa.eu/documents/10162/13555/common_approach_rac_seac_en.pdf)]

53 In contrast to the registration process in which only some registration dossiers are

1 assessed, all applications for authorisation are assessed by the Committee for Risk
 2 Assessment (RAC) and Committee for Socio-Economic Analysis (SEAC). The final opinion
 3 of the two Committees on the application is taken into account by the Commission who
 4 make the final decision on the application.

5 In view of the above and the fact, that applying for authorisation is primarily the result
 6 of a complex business decision, it must be stressed that the resources to be employed in
 7 preparing an application, including the risk assessment, go beyond those traditionally
 8 available in the environmental, health and safety department of a company.

9

10 **R.14.7.2 Assessment of Chemical Safety Reports by RAC**

11 In contrast to the registration process, every CSR in an authorisation application is
 12 assessed by RAC to form an opinion on authorising the use(s) identified in the
 13 application. It is essential that RAC can understand the processes and tasks described in
 14 the CSR and the underlying assumptions, justifications and conclusions in the exposure
 15 assessment. Therefore this section, describes how authorisation applications are
 16 evaluated and what kinds of uncertainties might be considered.

17

18 *1. Elements taken into consideration in the context of AfA*

19

20 The following four tables have been taken from the template for draft opinions for
 21 agreement for RAC and may be subject to change. However, they highlight the structure
 22 of the information requested.

23

24 **Table R.14- 4: Contributing Scenarios presented in the Use**

Contributing scenario	ERC / PROC	Name of the scenario
ECS1		
WCS 1		
WCS 2		

25

26 **Table R.14- 5: Operational Conditions and Risk Management Measures**

Contributing scenario	Duration and frequency of exposure	Concentration of the substance*	LEV used + effectiveness	RPE used + effectiveness	Skin protection+ effectiveness	Other RMMs
WCS 1 + PROC						
WCS 2+ PROC						

27 **If changing through the process*

28

1 **Table R.14- 6: Exposure – dermal and inhalation**

Contributing scenario	Route of exposure	Method of assessment	Exposure value	Exposure value corrected for PPE	Exposure value corrected for PPE and frequency *
WCS 1	Inhalation				
	Dermal				
WCS 2	Inhalation				
	Dermal				

2 *And duration of the task – if not already considered

3

4 **Table R.14- 7: Combined exposure**

Contributing scenario	Route	Exposure value corrected for PPE and frequency
WCS 1	Inhalation	
	Dermal	
WCS 2	Inhalation	
	Dermal	
Total exposure for 8 hours	Inhalation	
	Dermal	

5

- 6 • For the exposure assessment of workers, it is important to clearly describe the
 7 overall processes of the use applied for, as well as the sequence of tasks (and
 8 individual tasks – described in worker contributing scenarios (WCS)) performed by
 9 individual workers (Table R.14- 4). For this purpose diagrams and photos or short
 10 videos would be very helpful, provided that they are representative of the tasks and
 11 workplaces at stake.
- 12
- 13 • In the individual working contributing scenarios, the operational conditions and risk
 14 management measurements (Table R.14- 5), aiming to either adequately control the
 15 risk or to minimise as low as is practically and technically possible, should be
 16 presented. It is important to follow the hierarchy of controls; for apparent deviations
 17 from this principle clear justification should be given. Article 5 of the Carcinogen and
 18 Mutagens Directive (2004/37/EC) provides advice on prevention and reduction
 19 exposure measures that could be used.
- 20
- 21
- 22 • In addition to the description of the exposure of individual workers through separate

1 WCs (Table R.14- 6), the combined exposure, resulting from various tasks
2 performed by a worker during the 8 hour shift must also be presented (Table R.14-
3 7). The remaining exposure should be clearly stated before and after the use of
4 certain RMMs, especially in the case of using RPE.

- 5
- 6 • Some tasks are only performed a few times per year, (e.g. infrequent delivery of the
7 substance, batch production or maintenance carried out once or twice a year). For
8 carcinogenic substances, the dose response relationship may be used to correct for
9 the frequency of these tasks and express the remaining risk (i.e. taking into
10 consideration the implemented RMMs) and the associated dose using the whole year
11 as a time basis. This may not be adequate for other substances such as reprotoxic
12 substances, where a DNEL is normally used. In addition, it is important that the
13 short-term and full-shift exposure levels that are experienced during infrequent tasks
14 are properly understood and clearly stated to ensure suitable risk management
15 measures are in place.
- 16
- 17 • It is recommended to employ all the tools available to describe the exposure; this
18 includes use of measured data for exposure via inhalation or by the dermal route as
19 well as biomonitoring and the various exposure models (tier 1 or higher). A
20 combination of different tools for individual working contributing scenarios may prove
21 useful. The choice of the methods to estimate the exposure should be clearly
22 justified, especially when using models, with respect to their domain of applicability.
23
- 24 • Remaining uncertainties, not necessarily being of a statistical nature in the exposure
25 assessment (e.g. those related to the methodology used to estimate the exposure,
26 the variability of tasks and their duration), should clearly be stated and critically
27 discussed.

28

29 *2. Indicators for weak evidence*

30 The assessment of exposure for authorisation purposes is required to be detailed and
31 therefore any deficiencies in the data submitted may cause concern and result in more
32 stringent recommendations. The deficiencies may include:

- 33
- 34 • The assessment was not complete with respect to all relevant endpoints or routes of
35 exposure, e.g. for man via the environment local or regional scale was not
36 considered, or for workers, exposure through dermal route was omitted.
- 37 • The description of the use, processes and tasks were too brief and did not address
38 variability in terms of OCs and RMMs.
- 39 • Possible changes (e.g. increase in the tonnage of the substance used) were not
40 reflected in the exposure and impact assessment.
- 41 • The aggregation of tasks into an 8 hour shift value remained unclear: tasks were
42 not clearly identified.
- 43 • The representativeness of measured data was not clearly demonstrated by the
44 applicant, (e.g. too small a sample size, or contextual information on the
45 measurements; for which set of tasks were OCs and RMMs covered and even more

- 1 importantly were not covered by certain measurements; limit of detection not
2 specified).
- 3 • In cases covering multiple (hundreds/thousands) DU sites throughout Europe,
4 measurement data from very few locations in one or two countries (without
5 corroboration with modelling data), may be assessed as having “only limited
6 geographical coverage” and judged to have only “limited informative value”.
 - 7 • Not providing raw data covering the measurements or information on the
8 methodology of biomonitoring campaigns (in the application, or upon request).
 - 9 • Information as to why a specific model was used in exposure assessment: e.g.
10 either inadequate or completely missing explanation; input parameters not included
11 or the choice of them was not explained, especially in relation to selection of
12 PROCs; claimed effectiveness of certain RMMs not justified; A sensitivity analysis for
13 important input parameters not provided.
 - 14 • No justification for not using higher level RMM, e.g. containment in cases where the
15 technology is available.
 - 16 • Overreliance on Personal Protective Equipment.
 - 17 • No corroboration of measurement data with modelling results, especially where the
18 data set is limited to, for example, one measurement session.
 - 19 • Mistakes made in calculations of exposure.

20 Whilst there is a possibility for RAC to ask for clarifications in relation to points of
21 concern, the authorisation process does not allow sufficient time for the exchange of
22 additional information or for obtaining such information. Therefore, potential applicants
23 should carefully and comprehensively present their uses, and address potential issues in
24 their applications.

25 For the assessment of applications, RAC has developed a checklist. In addition, RAC has
26 developed an opinion tree to conclude on authorization opinions for non-threshold
27 substances. Applicants may find these documents useful when preparing their
28 applications (see [17] and [18]).

29
30
31
32

Appendix R.14-1. Exposure estimation models

A.14-1.1. ECETOC TRA tool for occupational exposure

The ECETOC TRA tool can be used to determine exposure through inhalation and by the dermal route. The ECETOC TRA tool can be downloaded from <http://www.ecetoc.org/tra>. The tool requires the user to input some basic information on the substance (molecular weight, vapour pressure, substance form). The user can then select contributing scenarios, as PROCs, which pre-define the point of departure exposure value. A range of exposure modifiers are sequentially applied to establish the set of operational conditions and risk management measures that appear in the final scenario.

A.14-1.1.1 Domain of applicability

The Table R.14- 8 below summarises those circumstances where the use of the TRA is not advised based on the information in ECETOC TRA version 3: Background and Rationale for the Improvements. Technical Report No. 114 [19]. The table only deviates from the above-mentioned ECETOC report in two entries:

- "CMRs and 'very high hazard' substances", where the limitations have been further clarified
- PROCs indicating closed systems (PROC 1-3). This entry has been added to the table to provide advice on the applicability domain of a PROC 1-3 exposure estimate in the using ECETOC TRA.

Table R.14- 8: Domain of reliable application of the TRAv3.1

Domain Boundary	Comments
Gases	The TRA does not predict exposure to gases. The reason for this is that the EASE model did not extend to gases. However the TRA does allow exposures to very volatile liquids (vapour pressure >10kPa and with no upper bound set on vapour pressure) to be estimated. As these very volatile liquids might be assumed to be the equivalents of gases for many circumstances of use (PROCs), then provided users are able to assure themselves of such equivalencies, then it is reasonable to assume that the high volatility exposure prediction can also be used to predict exposures to gases in certain scenarios.
Aerosol mists	Although exposures to aerosol mists might be expected to be associated with certain uses which are open and associated with the release of significant amounts of energy (e.g. spraying, machining, etc.), the TRA does not address such exposures. However, in circumstances where users have available representative measured exposure data on mists, then these may be able to be used to 'calibrate' and read across to relevant PROCs e.g. by assessing whether medium dustiness values might offer a conservative approximation of actual data (but where consideration also needs to be given to the vapour component of such exposures).

Comments	
Domain Boundary	
Process fumes	Although exposures to process fumes might be expected to be associated with certain uses which are undertaken at elevated temperatures (e.g. handling hot materials when their melting point lies at or above ambient temperatures), the TRA does not address such exposures. Appendix E of [19] addresses this aspect in further detail.
Fibrous materials	The TRA does not predict exposure to fibrous solids.
Exposures above ambient temperature	The TRA predicts exposure at 20°C. Where a liquid substance is handled at temperatures significantly in excess of this, then users should apply the vapour pressure calculated at the operating temperature. The exception to this 'rule' is PROC6 (calendaring) where the TRA predictions already account for the elevated temperatures applied in this activity (see also 'process fumes' above when solid substances are handled).
Solids in liquids	The TRA cannot predict inhalation exposures to solids suspended or dissolved in liquids. If such exposures are considered relevant, then in circumstances where users have available representative measured exposure data, then these may be able to be used to 'calibrate' and read across to relevant PROCs, or alternatively users are referred to other tools capable of estimating such exposures. The model will predict dermal exposures.
CMRs and 'very high hazard' substances e.g. respiratory sensitizers	Although the TRA is a Tier 1 model and hence is intended to be conservative in the nature of its predictions, it requires judicious interpretation if applied to CMRs and other high hazard substances. For 'simple' substances such as readily volatile liquids (e.g. toluene, benzene, n-hexane), the TRA will be capable of offering valid predictions, provided the practical use/exposure situation has been correctly translated to a suitable TRA process category and suitable exposure modifiers (i.e. risk management measures). CMRs and other highly hazardous substances are often handled under specific conditions to prevent and control exposure. Such conditions often cannot be readily translated into the available TRA inputs. Therefore assessors should have access to sets of measured exposure data for at least some of the PROC/RMM combinations for the substance (or close analogues) to establish that they are broadly consistent with the TRA estimates.

Comments	
Domain Boundary	
UVCBs	The TRA estimates have been developed for mono-constituent substances. Where UVCB substances are being assessed using the TRA (in particular those substances having a range of volatilities) then users should apply the nominal VP for the substance (or the VP of most volatile component present at >1% when this is known). If an UVCB material is handled at elevated temperatures, then further correction will need to be applied consistent with the guidance contained elsewhere in this section.
Mixtures	The concentration modifier enables the TRA to predict exposures to a single substance within a (simple) mixture. However, the TRA is not intended to be applied to calculate combined exposures to different substances in a mixture beyond the 'concentration banding' that already exists
Fractions of airborne solids	The TRA exposure predictions for solids do not differentiate between total inhalable exposure (respirable and non-respirable) and respirable exposures fractions. Users should therefore assume that any output for solids describes the inhalable fraction.

Comments	
Domain Boundary	
<p>PROCs indicating closed systems (PROC 1-3)</p>	<p>The TRA exposure prediction covers processes as typically applied in manufacturing and formulation of chemicals, pharmaceutical and mineral oil products (e.g. reaction, mixing, distillation purification, drying, charging/discharging) under closed conditions. If such processes are not undertaken under contained/closed conditions PROC 1-3 is not applicable: e.g. tray drying, dry milling and sieving, manual dis/charging to and from containers, filtration on nutsches and filter presses; stirred reactions in open or partially closed vessels;</p> <p>The TRA predictions for PROC 1 to 3 may be also applicable to end-uses, which are typically carried out under closed conditions (e.g. dry cleaning, metal cleaning, where the level of containment of machines is indicated by a sector classification system (e.g. ECSA). The following criteria define the applicability domain of a PROC 1-3 exposure estimate in the TRA:</p> <ul style="list-style-type: none"> • The process takes place in a high integrity contained, fully closed system (PROC 1) or in a closed system (PROC 2 and 3). It is not possible to break into the system during operation (PROC 1-3). • The transfers of materials into or from the system are undertaken by means of closed lines (PROC 1 and 2) or in an enclosed manner, where there is however some opportunity for exposure (e.g. during coupling/decoupling of lines (PROC 3). • Sampling is only done by i) means of dedicated, closed loop (fully closed) sampling systems, which prevent any contact of workers with the substance (PROC 1) or ii) by means of dedicated, enclosed sampling systems, which limit contact of workers with the substance (PROC 2 and 3) • Before breaking into (part of) the system for maintenance or cleaning, the system (or parts of it) is isolated, drained and flushed or purged to eliminate chemicals from the system (PROC 1-3). The drained/flushed/purged material is also contained (PROC 1)
<p>Out of scope PROCs</p>	<p>The TRA does not cover certain PROCs, specifically PROC 25 (handling of solid inorganic substances at ambient temperature); PROC 27a (production of metal powders using hot processes) and PROC 27b (production of metal powders using wet processes). If these PROCs are considered relevant, then users are referred to other tools capable of estimating exposure in these circumstances (e.g. MEASE).</p>

1 **Additional observation on applicability of the tool**

2 Some additional factors relating to exposure assessment require some consideration by
 3 registrants when using the ECETOC TRA tool. These are:

- 4 • The model allows the user to iterate a range of options leading to the final
 5 exposure scenario. The tool forbids some combinations of exposure modifiers.
 6 Users should not deviate from defaults without strong justification and evidence –

1 for example, enhancing glove effectiveness, amending duration of exposure, use
2 of LEV outdoors, or through introducing a linear relationship between exposure
3 output and concentration. The model applies its own means to adjust for these
4 variables and forbids some combinations. Attempts to reduce exposures by
5 application of unsupported and unjustified methods will make the assessment
6 invalid, unless the tool developers expressly state the action is a possibility.

- 7 • The tool predicts dermal exposure only to the hands (and in a few cases
8 forearms, depending on the PROC used). For some tasks, other body parts may
9 be additional targets for deposition. This will not be predicted by the model and
10 will need to be addressed separately if challenge to other body parts is a realistic
11 concern.
- 12 • Users of the tool may elect to opt for dermal exposure modification through use
13 of LEV. This may be a valid option in some cases, for example for highly volatile
14 substances and during industrial spray use where aerosol release is anticipated. It
15 is not often a justifiable choice for low volatility substances (low fugacity) where
16 surface contamination levels are largely not affected by the rate of evaporation
17 and are anticipated to be the primary source of potential exposure.
- 18 • Glove effectiveness is assigned within the model and associated with specific
19 phrases related to the level of organisational and management control. For
20 quantitative assessment it is anticipated that further exposure modification,
21 through extension of model defaults, will require justification; for instance using a
22 98% effectiveness¹⁶ modification factor outside of the model where this is
23 associated with a phrase for enhanced intensive management supervision
24 controls.

26 **A.14-1.1.2 Inputs**

27 The following determinants are needed as input data:

29 **Substance identification and Physical-chemical properties:**

30 As a minimum the following information should be included:

- 31 • Molecular weight
- 32 • Vapour pressure (Pa or hPa)

34 **Assessment inputs**

- 35 • Process Category (PROC)
- 36 • Type of setting (industrial/professional)
- 37 • Substance form (Solid or liquid)
- 38 • Vapour pressure at operation temperature (liquids/gases) or dustiness (solids)
- 39 • Duration of the activity
- 40 • Type of ventilation (Outdoors, general ventilation, LEV etc.)
- 41 • Respiratory protection (and if yes, minimum efficiency)
- 42 • Whether the substance is used in a mixture (then percentage of substance in the
43 mixture is chosen)
- 44 • Dermal PPE/ Gloves (and if yes, assigned protection factor (APF))
- 45 • Whether LEV for dermal exposure has been considered
- 46 • Reference value(s) (normally DNEL). Exposure estimates will be derived, even
47 without entering a reference value.

¹⁶ This level of performance and associated ECom phrase is appropriate where the substance is corrosive or a sensitizer and the intention is to prevent exposure through implementation of an intensive glove management programme. However, within quantitative estimation of exposure the 98% value has to be justified.

1
 2 In addition to these inputs that are needed to calculate exposures, some additional
 3 (optional) information may be added such us substance name, CAS number and
 4 short scenario name.

5 **A.14-1.1.3 Outputs**

6 **Table R.14- 9: ECETOC TRA Output**

ECETOC OUTPUT	
Exposure estimates	
Output	Unit
Long-term inhalation exposure estimate	(ppm and mg/m ³ for volatiles) / (mg/m ³ for solids)
Short-term Inhalation exposure estimate	(ppm and mg/m ³ for volatiles) / (mg/m ³ for solids)
Long-term dermal exposure estimate	(mg/kg/day)
Local dermal exposure estimate	(µg/cm ²)
Risk characterisation ratio*	
RCR - Long-term Inhalation	
RCR -Long-term Dermal	
RCR - Long-term Total Exposure	
RCR - Short-term Inhalation	
RCR - Local Dermal	

7 (*) Please note that the tool will not provide all these RCRs in all cases, as in many
 8 situations not all possible DNELs will have been derived.

9 **A.14-1.1.4 Status of validation**

10 The inhalation estimates of the TRA have been evaluated in a number of independent
 11 studies and have generally been found to be conservative ([20], [21], [22], [23], [15]
 12 and [24]) , although these exercises have not examined all the use situations (PROCs)
 13 and substance types dealt with by the TRA. The validations have also highlighted that, in
 14 practice, the exposure reduction afforded by LEV can be significantly less than that
 15 assumed by the TRA, for example, when such LEV is incorrectly located or poorly
 16 maintained, or higher in particular in cases of well-designed systems. It has been agreed
 17 that for REACH registrants it is reasonable to expect a standard of good occupational
 18 hygiene practice in European workplaces driven by existing legal requirements. Such
 19 good practice includes periodic testing and maintenance of RMMs. The TRA's ability to
 20 estimate dermal exposures has not yet been evaluated, although a CEFIC LRI supported
 21 study is examining this aspect and is expected to conclude by summer 2016. ECETOC
 22 continues to review the TRA estimates in the light of new scientific understandings as
 23 well as related developments, e.g. the updated PROC descriptions contained within the
 24 revised *Chapter R.12 of the IR&CSA Guidance* [9].

25

A.14-1.2. MEASE for metals and inorganic substances

MEASE has been developed to address first Tier exposure estimation of metals and inorganic substances. It combines the approaches from the ECETOC TRA tool, the EASE expert system and the health risk assessment guidance for metals (HERAG project) and generates first tier inhalation and dermal occupational exposure estimates. For inhalation exposure, the tool follows the PROC approach of the TRA tool and selects initial exposure estimates from three fugacity classes (low, medium, high). The fugacity classes are defined based on the physical form, the melting point of the metal/inorganic substance, the temperature of the process, the vapour pressure and the selected PROC.

For dermal exposure, MEASE is based on a system of exposure bands. However, the generated exposure estimates are based on measured data from several metals, collated and plotted against the EASE exposure classes in the "dermal fact sheet" of the HERAG project. The MEASE tool can be downloaded from <http://www.ebrc.de/mease.html> and the REACH metals gateway <http://www.reach-metals.eu/>

A.14-1.2.1 Domain of applicability

Table R.14- 10: Domain of intended application of MEASE 1.02.01 and MEASE 2

Type of exposure	Applicability information
General applicability domain	The MEASE tool is a first tier exposure assessment tool developed for the assessment of occupational inhalation and dermal exposure to metals and their inorganic compounds under REACH. It should not be used outside this applicability domain. The tool considers that existing parallel legislation to REACH (requiring, for example, a basic level of good occupational hygiene practice for compliance with the generic dust limit) is followed.
Gases	Exposure resulting from manufacture, processing and transfer of inorganic gases can be assessed for highly contained processes.
Aerosol mists	Exposure to aerosol mists is covered for the fraction of the (metal/inorganic) substance in airborne droplets. Compare with "Solids in liquids".
Solids in liquids	Exposure to solid (metal/inorganic) substances in liquids (e.g. aqueous solutions and suspensions) is covered by the tool.
Fibrous materials	Covered for inorganic materials.
Resulting from emissions from processes conducted above ambient temperature	Exposure resulting from emissions from processes conducted above ambient temperature is covered for the fraction of the (metal/inorganic) substance in airborne dust or droplets. It is assumed that workers are not exposed to hot aerosols for safety reasons. Compare with process fumes.
Process fumes	Exposure to process fumes is covered for the fraction of the (metal/inorganic) substance in airborne dust. It is assumed that workers are not exposed to hot fumes for safety reasons.

Mixtures	Covered, given that the substance in mixture falls into at least one of the covered types of exposure above.
UVCBs	Covered, given that the substance falls into at least one of the covered types of exposure above.
CMRs and 'very high hazard' substances e.g. respiratory sensitizers	Covered, given that the substance falls into at least one of the covered types of exposure above. However, it is strongly advised to confirm very low/no exposure situations, which are required in this case, by exposure monitoring data.
Fractions of airborne solids	Exposure estimates in MEASE are provided for the inhalable fraction of airborne dust (particles that can potentially be inhaled) according to EN 481.
Out of scope tasks/process (PROCs)	From the currently existing PROCs, none are generally out of scope. However, specific combinations of PROCs and physical forms are out of scope, e.g. combination of PROC 21 and physical form "Solid, high dustiness". A warning is given in these cases in the tool. PROC28 is in MEASE 2.

1

2 **A.14-1.2.2 Inputs**

3 The following determinants are needed as input data:

4 • **Substances characteristics:**

- 5 ○ Molecular weight (g/mol)
- 6 ○ Melting point (°C)
- 7 ○ Vapour pressure (Pa)
- 8 ○ Physical form
- 9 ○ Content in preparation (including alloys) (%)

10 • **Operational conditions (OC):**

- 11 ○ Process category (the tool itself provides some guidance on choosing the
- 12 right PROC)
- 13 ○ Process temperature (°C)
- 14 ○ Scale of operation (industrial/professional)
- 15 ○ Duration of the exposure

16 • **OCs used for dermal exposure assessment**

- 17 ○ Pattern of use (Wide dispersive, non-dispersive, inclusion into matrix or
- 18 closed system)
- 19 ○ Pattern of exposure control (direct/non direct handling)
- 20 ○ Contact level (extensive, intermittent, etc.)

21 • **Risk Management measures (RMM)**

- 22 ○ Implemented RMMs
- 23 ○ RMM efficiency (based on type of enclosure / ventilation)
- 24 ○ Respiratory protective equipment (APF)
- 25 ○ Use of gloves

26

27 **A.14-1.2.3 Output**

1 **Table R.14- 11: MEASE output**

MEASE OUTPUT	
Output	Unit
Long-term inhalation exposure estimate	mg/m ³
Long-term dermal exposure estimate	µg/cm ² /day
Exposed skin area	cm ²
Total dermal loading	mg/day

2

3 **A.14-1.2.4 Status of validation**

4 MEASE has been developed based on experiences from several EU risk assessments of
5 metals and their inorganic compounds (Ni, Cu, Zn, Pb, Sb). In these risk assessments,
6 monitoring data for occupational exposure were peer-reviewed and used for the
7 respective occupational exposure assessments. The associated databases were collated
8 by incorporating available contextual information and used for the calibration of MEASE.
9 The output of the MEASE model is constantly validated by comparison with more recent
10 monitoring data and the results are taken into account when updating the tool. However,
11 a systematic comparison of tool prediction and measured data sets has not been
12 published so far.

13 **A.14-1.3. EMKG-Expo-Tool**

14 The exposure prediction model of the German EMKG-Expo-Tool¹⁷ "Easy-to-use workplace
15 control scheme for hazardous substances" is a generic tool that can be used to derive a
16 Tier 1 inhalation exposure value for the workplace (EMKG, BAuA 2008). The tool was
17 developed to help small and medium sized companies to comply with the Chemical
18 Agents Directive. The EMKG-Expo-Tool is based on a chemical banding approach similar
19 to COSHH Essentials, originally developed by the UK Health and Safety Executive (HSE
20 1999). While COSHH Essentials is seen as a qualitative approach to guide the
21 assessment and management of workplace risks, the EMKG-Expo-Tool can also be used
22 as a generic tool for assessing and comparing the level of exposure with limit values
23 (OEL, DNEL). Hence, the EMKG-Expo-Tool should be seen as an approach for filtering the
24 non-risky workplace situations from those requiring detailed attention. The tool only
25 functions for inhalation exposure. The English version of the EMKG-Expo-tool is available
26 on the BAuA website: (www.baua.de), [http://www.reach-](http://www.reach-helpdesk.de/en/Exposure/Exposure.html)
27 [helpdesk.de/en/Exposure/Exposure.html](http://www.reach-helpdesk.de/en/Exposure/Exposure.html).

28 **A.14-1.3.1 Domain of applicability**

29 The EMKG-Expo-Tool is currently not appropriate for special situations, including

¹⁷ The acronym EMKG stands for "Einfaches Maßnahmenkonzept Gefahrstoffe".

1 activities where dusts are formed through abrasive techniques, open spray applications,
 2 gases, and pesticides. Operations that give rise to the generation of fumes (soldering,
 3 welding) and wood dusts are exempted as well. The tool is also not suited for CMR
 4 substances. These situations involve more complex exposures requiring additional
 5 considerations that are not yet fully addressed by the current tool.

6 **A.14-1.3.2 Inputs**

7 The following determinants are needed as input data:

- 8 • type of substance: solid/liquid
- 9 • dustiness (for solids), based on particle size and observation when substance is
 10 used
- 11 • or volatility for liquids (estimated from the vapour pressure at process
 12 temperature or if this is not available from a combination of boiling point and
 13 process temperature)
- 14 • operational conditions (temperature, amount of substance/product used per task,
 15 size of the application surface)
- 16 • implemented RMMs (control strategy)
- 17 • exposure period (<15 min or > 15 min)

18
 19 These general control solutions are underpinned by a series of Control Guidance Sheets
 20 (CGS) which provide practical examples of each control approach for common industrial
 21 unit operations such as weighing and filling. The CGS are essential to demonstrate a safe
 22 use and there are a number of key points that the user has to follow to control exposure,
 23 e.g. access to the work area, design and equipment, maintenance of equipment,
 24 examination and testing of equipment, cleaning and housekeeping, personal protective
 25 equipment, training, supervision. The Control Guidance Sheets can be accessed directly
 26 through the following link: [http://www.reach-clp-biozid-](http://www.reach-clp-biozid-helpdesk.de/en/Exposure/Exposure.html)
 27 [helpdesk.de/en/Exposure/Exposure.html](http://www.reach-clp-biozid-helpdesk.de/en/Exposure/Exposure.html).

28 **A.14-1.3.3 Outputs**

29 **Table R.14- 12: EMKG-Expo-Tool OUTPUT version 2.2**

EMKG-Expo-Tool OUTPUT	
For solids	
Output	Units
Exposure band (for long-term inhalation exposure)	In mg/m ³ (for RCR take the higher value of the band)
For liquids	
Output	Units
Exposure band (for long-term inhalation exposure)	In ppm (for RCR take the higher value of the band)

30

31 **A.14-1.3.4 Status of validation**

32 For liquids, Lamb et al [15] carried out an extensive comparison of measured data (n=
 33 905) with model predictions to examine the level of conservatism. "High", "medium" and
 34 "low" levels of conservatism were defined as where ≤ 10 %, 10 ≤ 25 % and > 25 % of
 35 the measurements exceeded the tool estimate, respectively. The EMKG-Expo-Tool

1 showed a medium level of conservatism for PROC 4, PROC 13, PROC 14, PROC 19, and
2 was highly conservative for PROC 5, PROC 8a, PROC 8b, PROC 9, and PROC 10 (see
3 table 3.32 in [15]).

4 A number of further studies aimed at the evaluation of the exposure prediction model of
5 COSHH Essentials. While Kindler [25], Lee et al [26] Hashimoto et al [27] and Tischer et
6 al [28] generally confirm the conservatism of model estimates for volatile liquids as
7 found by Lamb et al, the papers of Lee et al ([29]-batch-making and bucket washing),
8 and Jones et al ([30]- vapour degreasing) described tasks where the tool tended to
9 underestimate exposure.

10
11 For solids, according to Lamb et al [15] (n=246) the EMKG-Expo-Tool was of
12 medium/high conservatism for powder handling tasks related to PROC 8b/9 respectively.
13 By contrast, the tool showed a low level of conservatism for PROC 5, PROC 8a, and PROC
14 14 (s. table 3.32 in [15]).

15 Evaluation of COSHH Essentials¹⁸ for bag filling operations carried out by Jones et al [30]
16 identified 48 % of bag filling operations as “under-controlled”.

17 For situation where the tool showed low levels of conservatism, it is recommended to
18 estimate the exposure by alternative means as well, in order to reduce the uncertainty in
19 the outcome. This may include, for example, comparison of modelled exposure values
20 from different models and comparison between measured exposure data and modelled
21 exposure estimates.

22

23 **A.14-1.4. Higher Tier exposure assessment**

24 If an initial assessment of exposure is not adequate, i.e. safe use is not reliably
25 demonstrated, a refined assessment is necessary. This assessment is generally more
26 specific than the initial assessment and may introduce new factors to be considered. The
27 refined assessment can use any suitable method that is valid and provides sufficient
28 accuracy. Higher tier assessments usually require input from experienced assessors.

29 Four models are briefly discussed in this guidance:

- 30 • Stoffenmanager (Section A.14-1.4.1),
- 31 • RISKOFDERM (Section A.14-1.4.2)
- 32 • BEAT (Section A.14-1.4.3)
- 33 • Advanced REACH Tool (ART) (Section A.14-1.4.4)

34 Exposure assessment models that have been developed for the exposure assessment of
35 biocides¹⁹ and pesticides can be applied for some worker exposure assessments. These
36 tools are particularly relevant for estimating dermal exposure and can estimate aerosol
37 exposure. The tools exist either as individual models within the Biocides Human Health
38 Exposure Methodology Document or have been further developed to be part of the
39 Bayesian Exposure Assessment Toolkit (BEAT model). Biocides models specifically

¹⁸ With regard to the EMKG-Expo-Tool it is important to note that the tool is almost identical to the exposure prediction model of the COSHH Essentials. Hence studies that aim at the validation of the COSHH Essentials can be used for the EMKG-Expo-Tool as well.

¹⁹ Guidance on the BPR: Volume III Human Health, Part B Assessment (Chapter 3 Exposure assessment) [<http://echa.europa.eu/web/guest/guidance-documents/guidance-on-biocides-legislation>]

Biocides Human Health Exposure Methodology Document [<http://echa.europa.eu/about-us/who-we-are/biocidal-products-committee/working-groups/human-exposure>]

1 allow prediction of dermal exposure and to aerosols for analogous situations based on
 2 underpinning real generic data which can be fully accessed via the BEAT model.
 3 In the USA, the Environmental Protection Agency (EPA) has supported development of a
 4 number of tools which may contain useful approaches for higher tier exposure
 5 assessment. Look at the EPA website for these approaches
 6 <http://www.epa.gov/expobox/exposure-assessment-tools-routes>
 7 If an initial exposure assessment does not produce an acceptable outcome it may be
 8 possible to produce exposure predictions that are specific to the exposure scenario.
 9 Levels clearly above DNELs, will demand the further development of exposure scenarios
 10 implementing a different set of operational conditions and risk management measures.

11 **A.14-1.4.1 Stoffenmanager**

12 Stoffenmanager version 6.4 (Dutch for "substance manager") is a web-tool that is free
 13 to use following registration. Besides the free version, it also has a commercial Premium
 14 version. Stoffenmanager includes a quantitative model for estimating inhalation
 15 exposure to vapours, aerosols of low volatility liquids and inhalable dusts. The model is
 16 available in Dutch, English, German, Finnish, Polish and Swedish. The web-based tool
 17 has a specific REACH section and a section for exposure calculations in which full shift
 18 time-weighted averages can be calculated. An exposure database containing around
 19 1000 measurements with all relevant Stoffenmanager parameters is used to further
 20 underpin and validate the model. The Stoffenmanager 6.3 exposure model tool is
 21 currently somewhere between first tier and higher tier models. The rationale of the
 22 underlying exposure algorithm is based on work of Cherrie and Schneider (1999) but is
 23 adapted in several ways (see <https://stoffenmanager.nl/Public/Explanation.aspx> for
 24 more information). Stoffenmanager estimates task-based exposure levels in mg/m³. A
 25 time-weighted average can be calculated for one, or several combined tasks with
 26 duration of less than 8 hours.

27 **A.14-1.4.1.1. Applicability domain**

28 The domain of application of Stoffenmanager [31] is summarized in Table R.14- 13.

29 **Table R.14- 13: Domain of reliable application of Stoffenmanager® (the algorithms can**
 30 **only be found at www.stoffenmanager.nl in its most recent version)**

Domain Boundary	Comments
Gases	Out of applicability domain
Aerosol Mists	Falls within applicability domain
Process fumes	Out of applicability domain
Fibrous materials	Out of applicability domain
Exposures above ambient temperature	Stoffenmanager predicts exposure at 20°C. Where a liquid substance is handled at temperatures significantly in excess of this, then users should apply the vapour pressure calculated at the operating temperature

Domain Boundary	Comments
Solids in liquids	Falls within applicability domain
CMRs and 'very high hazard' substances e.g. respiratory sensitizers	Falls within applicability domain
UVCBs	Falls within applicability domain
Mixtures	Falls within applicability domain
Fractions of airborne solids	<p>Falls within applicability domain for abrasive activities using wood (inhalable dust) and stone (inhalable and respirable dust).</p> <p>Out of applicability domain for other abrasive activities like using plastic, glass or metal.</p>
Out of scope tasks/process (PROCs)	<ul style="list-style-type: none"> - PROC 6 Calendering operations - PROC 12 Use of blowing agents in manufacture of foam - PROC 16 Using material as fuel sources, limited exposure to unburned product to be expected - PROC 20 Heat and pressure transfer fluids in dispersive, professional use but closed systems - PROC 21 Low energy manipulation of substances bound in materials and/or articles. Abrasive activities using wood (inhalable dust) and stone (inhalable and respirable dust) do fall within the scope. - PROC 22 Potentially closed processing operations with minerals/metals at elevated temperature. Industrial setting - PROC 23 Open processing and transfer operations with minerals/metals at elevated temperature - PROC 24 High (mechanical) energy work-up of substances bound in materials and/or articles. Abrasive activities using wood (inhalable dust) and stone (inhalable and respirable dust) do fall within the scope. - PROC 25 Other hot work operations with metals - PROC 27a Production of metal powders (hot processes) - PROC 27b Production of metal powders (wet processes)

1 **A.14-1.4.1.2. Input data**

1 The following parameters are needed as input data for the quantification of exposure
2 with the Stoffenmanager:

- 3 • Physical state of the substance (solid or liquid)
- 4 • Whether there are activities involving articles (= solid objects) that may cause
5 emission of dust.
- 6 • Vapour pressure of liquids (in Pascal, used directly) or dustiness (solid articles,
7 firm granules or flakes, granules or flakes, coarse dust, fine dust, extremely dusty
8 products)
- 9 • Type of dust emitted from solid objects (presently only stone or wood)
- 10 • Percentage of the substance(s) in the product
- 11 • Level of dilution of liquid products with water (undiluted = 100%)
- 12 • Handling category
- 13 • Duration and frequency
- 14 • Local controls (including local exhaust ventilation (LEV) and containment)
- 15 • Distance of the worker from the source (within one meter or not)
- 16 • Presence of secondary emission sources:
 - 17 ○ Other workers using the same substance simultaneously
 - 18 ○ A period of evaporation, drying or curing after the activity (with prolonged
19 emission of vapours)
- 20 • Room volume
- 21 • General ventilation
- 22 • Emission control measures (such as control rooms)
- 23 • Respiratory protective equipment (RPE) used
- 24 • Information on whether the work area is regularly cleaned
- 25 • Information on whether machinery and equipment are regularly inspected and
26 kept in good order.

27 To calculate time weighted averages, separate assessments for each activity should first
28 be made and then combined using the duration of each activity entered to calculate time
29 weighted averages.

30 In addition to the required inputs for exposure estimation, a number of other inputs are
31 needed. These are data on the product name, the date of the Safety Data Sheet, the
32 name of the supplier as well as the department or work area for which the assessment is
33 being made. Although these data will not influence the quantitative calculations, inputs
34 are required for the software to function.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

A.14-1.4.1.3. Stoffenmanager output

Table R.14- 14: Stoffenmanager output

STOFFENMANAGER OUTPUT	
Output	Units / comments
Long-term inhalation exposure estimate	mg/m ³ (90th percentile)
Short-term inhalation exposure estimate	mg/m ³ (90th percentile)
Data on the exposure distribution	The tool gives the 50-75-90 and 95 percentile values of the exposure distribution. The 90th percentile is given as default value

A.14-1.4.1.4. Status of validation

Stoffenmanager® is a continuous development platform and the algorithms in its most recent version can only be found at www.stoffenmanager.nl. The International Scientific Advisory Board is a guarantee that the tool complies with regulations and is in line with latest scientific developments. Several publications concerning the development and further refinement of the model are available. Originally the tool is based on a published scientific conceptual model of exposure [32] followed by a quantification of the model algorithms (i.e. the calibration with measured data) by [33]. Schinkel et al. [34] published a cross-validation and further refinement of the model and concluded that the 90th percentile estimates of the model are verified to be sufficiently conservative and therefore can be used as tier 1 exposure assessment tool for REACH. This was again demonstrated by Koppisch et al. [35] who focussed on estimating workers exposure to inhalable dust. In the ETEAM study all five REACH tier I tools were evaluated and the authors concluded that Stoffenmanager® 4.5 appeared to provide the most balanced performance with regard to the level of conservatism and predictive power for volatile liquids and powders ([15] and [36]). In another study, Landberg et al. [37] evaluated the conservatism of Stoffenmanager® 5.1 by testing whether the 90th percentiles are above the measured exposure values. They showed that only two of the eleven scenarios tested had slightly higher measured median exposure values than modelled concentrations and concluded that the model performed well. Finally a sensitivity analysis on ECETOC TRA v3, Stoffenmanager® 4.5 and ART 1.5 was performed by Riedmann et al. [24] to determine dominant factors for the three models and to assess the robustness of each model. The authors stated that, "when the entry data are uncertain or difficult to use, practitioners should consider using Stoffenmanager as their default occupational exposure model since: (1) it provides mean exposure estimates and various CIs in a reasonable range, and (2) it is the most robust model. Besides, Stoffenmanager appears also to be the most balanced model with regard to physical phenomena such as source emission and dilution." Overall, the conclusion, on the basis of all available scientific literature, is that the Stoffenmanager® model is robust, has sufficiently predictive power and is conservative enough for a REACH tier 1 tool.

A.14-1.4.2 RISKOFDERM

The RISKOFDERM dermal exposure model is the result of a European 5th framework programme project that focused on dermal exposures in industrial and professional settings [38]. The model assesses mainly potential dermal exposure, i.e. exposure on the skin and on the outer layers of clothing covering the skin in the target areas. It therefore does not take into account any protective effect of clothing or gloves, unless specified. Performance of protective clothing and gloves has to be introduced externally to the model to produce an estimate of actual dermal exposure (ADE) which can be used to compare with an external DNEL. The model is based on real datasets with known distributions that represent much of the current knowledge on dermal exposure in the professional and industrial setting.

An Excel spreadsheet version of, and a guidance document for, the model can be downloaded from <http://www.eurofins.com/product-testing-services/services/research-development/projects-on-skin-exposure-and-protection/riskofderm-skin-exposure-and-risk-assessment.aspx>

The basic estimate made by RISKOFDERM is the potential rate of exposure per minute (for hands and/or remainder of the body). Total exposure over a longer period is calculated by entering the duration of the activity leading to exposure.

Although the potential for deposition may, at times, appear high, especially when compared to other models, there is consistency between a wide range of studies in this area.

The exposure reducing effect of protective clothing and gloves needs to be included externally to the model. Advice, which may be useful by analogy, on the effectiveness of gloves and clothing can be found in work carried out in the context of biocides and incorporating findings from a number of studies on the effectiveness of protective clothing (Please see http://echa.europa.eu/documents/10162/19680902/heeg_opinion_9_default_protection_factors_for_clothing_and_gloves_en.pdf).

A.14-1.4.2.1. Domain of Applicability

Due to a lack of data on dermal exposure to volatile substances, the model is not optimally suitable for very volatile substances (e.g. > 500 Pa vapour pressure). Use with input values outside those found in the measured data sets should be avoided, though results may still be indicative. These boundaries are provided in the guidance document with the spreadsheet version (that can be downloaded from <http://www.eurofins.com/product-testing-services/services/research-development/projects-on-skin-exposure-and-protection/riskofderm-skin-exposure-and-risk-assessment.aspx>). Further refinement of predictions of actual dermal exposure may be provided through application of other external tools such as IH SkinPerm.

A.14-1.4.2.2. Input data

The first step in using the RISKOFDERM dermal exposure model is to input the type of exposure process (choice between one of six processes or DEO units). The next step depends on the exposure process input and the following items may be needed:

- type of skin contact
- frequency of skin contact
- type of product handled
- viscosity of the product
- volatility of the product
- dustiness of the product

- 1 • use rate of the product
- 2 • formation of aerosols
- 3 • manual or automated tasks
- 4 • direction of application
- 5 • tools used
- 6 • quality of ventilation
- 7 • direction of airflow
- 8 • segregation of worker from source
- 9 • distance of worker from sources

10 **A.14-1.4.2.3. Output**

11 The spreadsheet version of the RISKOFDERM dermal model provides exposure estimates
12 for the median exposure level corresponding to the inputs provided and for any chosen
13 percentile. Also, the values are presented for a number of fixed percentiles of the output
14 distribution. Depending on the exposure process only hand exposure, only body
15 exposure or both are estimated.

16 The web-based version provides a distribution of exposure estimates for the input
17 distributions provided. The RISKOFDERM dermal exposure model makes calculations
18 based on equations derived from mixed-model statistical analyses from a relatively large
19 set of measured data.

20 **A.14-1.4.2.4. Status of validation**

21 The validity of the model has not been established with independent data. A benchmark
22 study after a first draft version showed that in general the model appeared to be quite
23 reasonable. The validity and adequacy of the model is relatively well-known for
24 situations resembling those measured in the data set that was the basis for the model
25 [38]

26 **A.14-1.4.3 BEAT model**

27 The Bayesian Exposure Assessment Tool (BEAT) was originally developed in 2002 by the
28 United Kingdom's HSE for experienced assessors undertaking regulatory risk
29 assessments carried out in connection with the European Biocidal Products Directive (EC,
30 1998a). The BPD has been replaced by the Biocidal Products Regulation (EU 528/2012)
31 and new Guidance²⁰ has been published for the BPR replacing the TNGs. BEAT provides
32 the option to search for appropriate generic data (suitable indicative exposure estimates)
33 based on (task) analogy with measured exposure data. In addition, the software offers a
34 hierarchical Bayesian model for probabilistic predictions by using various analogous data
35 sets in a single exposure distribution. In addition, if sufficient data for an analysis are
36 available, BEAT offers further statistical tools (e.g. Markov Chain Monte Carlo analysis).
37 A feature of BEAT is that users are not restricted to using exposure values extracted
38 from the measurement database; instead, the user may insert other data. Moreover,
39 BEAT provides a visualization of the spatial distribution of dermal exposure of the body
40 using three-dimensional mapping (IGHRC, 2010). General information about the

²⁰ Guidance on the BPR: Volume III Human Health, Part B Assessment (Chapter 3 Exposure assessment)
[<http://echa.europa.eu/web/guest/guidance-documents/guidance-on-biocides-legislation>]

Biocides Human Health Exposure Methodology Document [<http://echa.europa.eu/about-us/who-we-are/biocidal-products-committee/working-groups/human-exposure>]

1 development and the underlying concept are provided in the help files integrated in the
2 tool, but details about the underlying algorithm are not publicly available. The BEAT
3 model is available at <http://xnet.hsl.gov.uk/download/>.

4 **A.14-1.4.3.1. Input data**

5 The following input data are required to run BEAT:

- 6 • physical state (liquid/solid)
- 7 • Particle size (e.g. sand like, pellets)
- 8 • Particle wetness (e.g.: dry, damp)
- 9 • viscosity of the product
- 10 • volatility of the product
- 11 • work environment (confined, restricted, open)
- 12 • automation of the process (e.g. fully manual, partly automated)
- 13 • type of ventilation
- 14 • whether liquid bases dust control is used
- 15 • Type of process (high energy/low energy)
- 16 • Spray pressure (e.g. showering, high pressure)
- 17 • Segregation of worker from source (e.g. partial segregation, containment)
- 18 • Surface area of contact (e.g. whole body, whole hands, fingertips)
- 19 • Level of contamination (e.g. invisible, thin layer)
- 20 • frequency of skin contact (e.g. rare, intermittent)
- 21 • Application use rate ($l \cdot \text{min}^{-1}$ or $\text{kg} \cdot \text{min}^{-1}$)
- 22 • Distance to source
- 23 • Length of tool handle
- 24 • Orientation (e.g. overhead, level)
- 25 • Duration of exposure (in minutes)

26 **A.14-1.4.3.2. Output**

27 Dermal exposure is provided as actual dermal exposure (mass rate) of the hands and
28 potential exposure of the body (in $\text{mg} \cdot \text{min}^{-1}$) for both a specific defined area of the skin
29 and a specific application rate presented in the database.
30

31 **A.14-1.4.3.3. Status of validation**

32 The BEAT dermal exposure tool has not been validated

33 **A.14-1.4.4 Advanced REACH Tool (ART)**

34 The Advanced REACH Tool, ART (version 1.5) makes use of mechanistically modelled
35 estimates of exposure and any relevant measurements of exposure. The tool provides
36 estimates of the whole distribution of exposure variability and uncertainty, allowing the
37 user to produce a variety of reasonably foreseeable realistic and worst-case exposure
38 estimates, dependent upon the requirements of the particular risk assessment. ART does
39 not take into account the effect of respiratory protective equipment (RPE). Performance
40 of RPE has to be introduced externally to the model to produce an estimate of actual
41 inhalation exposure which can be used to compare with an external DNEL. The approach
42 facilitates the inclusion of any new data that become available in the future or during the

1 risk assessment process. The tool is suitable for expert assessors.
 2 Since the tool allows the use of analogous exposure data from comparable scenarios,
 3 exposure assessments will not automatically require scenario-specific exposure data
 4 [39]. The tool incorporates both a mechanistic model and an empirical part with
 5 information from an exposure database.
 6 ART is a web-tool that is free to use following registration. Registration is via the website
 7 <http://www.advancedreachtool.com>.

8 **A.14-1.4.4.1. Domain of applicability**

9 The domain of applicability of ART is summarized in Table R.14- 15 below.

10 **Table R.14- 15: domain of applicability of ART**

Type of exposure	Explanation
Exposure types within ART applicability domain	
Dust	Solid particles that are formed by aerosolization of already existing powders or by abrasion of solid objects.
Mist	Any airborne liquid particles. A water mist in the form of fog or a fine spray is a common example.
Vapour	This is the airborne state of a chemical, which, if a sufficiently large amount of liquid were released into a closed room at normal temperature, would not completely evaporate but rather would reach equilibrium with its liquid. Exposure during the application of various organic solvents is a common example.
Fume	Solid particles that are formed by condensation from high temperature vapour, such as from molten metal or smoke
Exposure types outside of ART applicability domain	
Gas	This is the airborne state of a chemical whose liquid is so volatile that its vapours cannot reach equilibrium with its liquid
Fibres	Elongated particles whose length-to-diameter ratio is at least 3:1 (e.g., asbestos, MMMF).

11
 12 **A.14-1.4.4.2. Input data**
 13 The inputs are arranged in sets of 'principal modifying factors' (MF) such as intrinsic
 14 emission rates, efficacy of local controls and methods of handling or processing of
 15 chemicals. Based on a relatively abstract definition of the MFs, specific inputs
 16 (determinants) have been derived. The user of the tool is guided through these inputs.
 17 For calculation of exposure with the mechanistic model the following inputs are needed:
 18

- Duration of activities (each will get a separate assessment) within the shift

- 1 • Type of material used (powdered, granular or pelletised material; solid objects;
2 liquids; powders dissolved in a liquid or incorporated in a liquid matrix; paste,
3 slurry or clearly (soaked) wet powder)
- 4 • For powdered, granular or pelletised material:
 - 5 ○ Dustiness (measured) or dustiness category
 - 6 ○ Moisture content of the material
- 7 • For solid objects:
 - 8 ○ Material of which the solid object is composed
 - 9 ○ Moisture content of the material
- 10 • For liquids:
 - 11 ○ Temperature of liquid in process (or relative compared to room
12 temperature)
 - 13 ○ Vapour pressure of the liquid
 - 14 ○ Boiling point of the liquid
 - 15 ○ Viscosity of the liquid
 - 16 ○ Activity coefficient of the substance in the liquid
- 17 • For all materials: molar or weight fraction of the substance in the material
- 18 • Primary emission source in the breathing zone of the worker (yes/no)
 - 19 ○ If yes, secondary sources outside the breathing zone also need to be
20 assessed.
- 21 For both primary and secondary emission sources, the following information has to be
22 provided separately:
 - 23 • Activity class of the activity
 - 24 ○ In some cases, also activity subclasses are defined
 - 25 ○ For some activity classes, further questions are asked, such as:
 - 26 ▪ Spray direction (for spraying)
 - 27 ▪ Drop height (for dropping of material, e.g. in transfer)
 - 28 ○ For several activity classes a parameter representing the 'scale' of the
29 activity needs to be provided (in classes), e.g. 'use rate' or 'surface area'
- 30 For primary sources (both within and outside the breathing zone), the following
31 information on RMM needs to be provided
 - 32 • Any control measures close to the source with the following choices and sub-
33 options
 - 34 ○ Suppression techniques (only for powdered, granular or pelletised
35 material)
 - 36 ○ Containment without extraction
 - 37 ○ Local exhaust ventilation - three options, each with two to three sub-
38 options
 - 39 • Measures to limit surface contamination and fugitive emissions
 - 40 ○ Enclosure of process
 - 41 ○ Evidently effective housekeeping

- 1 ○ General housekeeping
- 2 • Conditions and measures of dispersion
- 3 ○ Working indoors, outdoors or in a spray room
- 4 ▪ For indoors: room size and ventilation rate
- 5 ▪ For outdoors: placement of source relative to buildings and of
- 6 workers relative to source

7 For primary sources outside of the breathing zone, only the following RMMs need to be
 8 evaluated:

- 9 • Emission source segregated from the worker (several options)
- 10 • Worker separated from the emission source by a personal enclosure (several
- 11 options)

12 For secondary sources (outside the breathing zone), the question regarding emission
 13 sources segregated from the worker also applies.

14 In addition, some administrative data on e.g. the name of the substance and the name
 15 of the assessment are also required to perform calculations.

16 **A.14-1.4.4.3. Output data**

17 ART version 1.5 (July 2014) provides the following outputs.

18 **Table R.14- 16: ART output**

ART OUTPUT	
Output	Units
Long-term inhalation exposure estimates (2 types)	<p>mg/m³</p> <p>Full-Shift exposure (recommended for REACH evaluations): ART calculates an overall distribution for full-shift exposures. Normally the 90th percentile (that provides the exposure level, which has a 10% probability of being exceeded by the exposure from a randomly selected worker on a randomly selected day) should be used for REACH purposes.</p> <p>mg/m³</p> <p>Long-Term Average exposure: ART calculates the distribution of workers' long-term average (mean) exposure (e.g. over a period of months). In this case, the 90th percentile provides the long-term mean exposure level, which has a 10% probability of being exceeded by the long-term exposure from a randomly selected worker.</p>
Short-term inhalation exposure estimates	mg/m³
Data on the exposure distribution	The tool generates values for 50th, 75th, 90th, 95th and 99th percentile exposures and applies a confidence interval around the reported value.

1

2 **A.14-1.4.4.1. Status of validation**

3 An evaluation of the tool predictions against an independent set of modelled data has
4 not been published yet.

5

6

1
2
3

REFERENCES

- [1] ECHA, "Guidance on Information requirements and chemical safety assessment. Chapter R.8 : Characterisation of dose [concentration]- response for human health," [Online]. Available: <http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.
- [2] CEN, "Workplace atmospheres. Size fraction definitions for measurement of airborne particles. EN 481," European Committee for Standardization (CEN).
- [3] CEN, "Workplace exposure - Procedures for measuring a chemical agent present as a mixture of airborne particles and vapour - Requirements and test methods. EN 13936," European Committee for Standardization (CEN).
- [4] CONCAWE, "Report 8/15: Monitoring method for inhalation exposure to gas oil vapour and aerosol," 2015. [Online]. Available: <https://www.concawe.eu/publications/539/40/Monitoring-method-for-inhalation-exposure-to-gas-oil-vapour-and-aerosol-report-no-8-15>.
- [5] CEN, "Workplace exposure. General requirements for the performance of procedures for the measurement of chemical agents. EN 482," European Committee for Standardization (CEN).
- [6] ECHA, "Guidance on Information requirements and chemical safety assessment. Part B : Hazard Assessment," [Online]. Available: <http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.
- [7] ECHA, "Illustrative example for CSR," [Online]. Available: <http://echa.europa.eu/support/practical-examples-of-chemical-safety-reports>.
- [8] ECHA, "Guidance on Information requirements and chemical safety assessment. Part E : Risk Characterisation," [Online]. Available: <http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.
- [9] ECHA, "Guidance on Information requirements and chemical safety assessment. Chapter R.12 : Use description," [Online]. Available: <http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.
- [10] ECHA, "Guidance on intermediates," [Online]. Available: <http://echa.europa.eu/guidance-documents/guidance-on-reach>.
- [11] W. Fransman, J. Schinkel, T. Meijster, J. Van Hemmen, E. Tielemans and H. Goede, "Development and Evaluation of an Exposure Control Efficacy Library (ECEL)," *Ann. Occup. Hyg.*, vol. 52, no. 7, pp. 567-575, 2008.
- [12] ECHA, "Guidance on Information requirements and chemical safety assessment. Part D : Framework for exposure assessment," [Online]. Available:

<http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.

- [13] CEN, "Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy. EN 689," European Committee for Standardization (CEN).
- [14] ECHA, "Guidance on Information requirements and chemical safety assessment. Chapter R.19 : Uncertainty analysis," [Online]. Available: <http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.
- [15] J. Lamb, S. Hesse, B. G. Miller, L. MacCalman, K. Schroeder, J. Cherrie and M. van Tongeren, "Evaluation of Tier 1 Exposure Assessment Models under REACH (eteam) Project-Final Overall Project Summary Report," 2015. [Online]. Available: <http://www.baua.de/de/Publikationen/Fachbeitraege/F2303-D26-D28.html>. [Accessed 2016].
- [16] R. Tibaldi, W. ten Berge and D. Drolet, "Dermal absorption of chemicals: estimation by IH SkinPerm.," *Journal of Occupational and Environmental Hygiene*, vol. 11, no. 1, pp. 19-31, 2014.
- [17] RAC and SEAC, "Guidance Paper on Opinion Trees for Non-Threshold Substances in Applications for Authorisations (AfA)," [Online]. Available: http://echa.europa.eu/documents/10162/13637/opinion_trees_non_threshold_sub_en.pdf.
- [18] RAC, "Checklist for evaluating chemical safety assessment in applications for authorisation," [Online]. Available: http://echa.europa.eu/documents/10162/13637/checklist_eval_csa_in_afa_en.pdf.
- [19] ECETOC, "ECETOC TRA version 3: Background and Rationale for the Improvements. Technical Report No. 114," 2014.
- [20] S. Vink, J. Mikkers, T. Bouwman, H. Marquart and E. Kroese, "Use of read-across and tiered exposure assessment in risk assessment under REACH – A case study on a phase-in substance," *Regulatory Toxicology and Pharmacology*, vol. 58, no. 1, pp. 64-71, 2010.
- [21] M. Kupczewaka-Dobecka, S. Czerczak and M. Jakubowski, "Evaluation of the TRA ECETOC model for inhalation workplace exposure to different organic solvents for selected process categories.," *International Journal of Occupational Medicine and Environmental Health*, vol. 24, no. 2, pp. 208-217, 2011.
- [22] E. Hofstetter, J. Spencer, K. Hiteshew, M. Coutu and M. Neally, "Evaluation of recommended REACH exposure modeling tools and near field, far field model in assessing occupational exposure to toluene from spray paint," *Ann. Occup. Hyg.*, vol. 57, no. 2, p. 210-220, 2013.
- [23] W.-K. Ko and Y.-S. Yi, "A Study on the Risk Assessment by Comparing Workplace Environment Measurement with Exposure Assessment Program (ECETOC TRA)," *Journal of the Korea Safety Management and Science*, vol. 15, pp. 1-6, 2013.

- [24] R. Riedmann, B. Gasic and D. Vernez, "Sensitivity Analysis, Dominant Factors, and Robustness of the ECETOC TRA v3, Stofenmanager 4.5, and ART 1.5 Occupational Exposure Models, Risk Analysis," *Risk Analysis*, vol. 35, no. 2, pp. 211-25, 2015.
- [25] P. Kindler and R. Winteler, "Anwendbarkeit von Expositionsmodellen für Chemikalien auf Schweizer Verhältnisse Teilprojekt 1: Überprüfung der Modelle ""EASE"" und ""EMKG-Expo-Tool""," 2010. [Online]. Available: <http://www.seco.admin.ch/themen/00385/02071/02248/index.html?lang=de>.
- [26] E. Lee, M. Harper, R. Bowen and J. Slaven, "Evaluation of COSHH Essentials: Methylene Chloride, Isopropanol, and Acetone Exposures in a Small Printing Plant," *Ann. Occup. Hyg.*, vol. 53, no. 5, pp. 463-474, 2009.
- [27] H. Hashimoto, T. Goto, N. Nakachi, H. Suzuki, T. Takebayashi, S. Kajiki and K. Mori, "Evaluation of the control banding method--comparison with measurement-based comprehensive risk assessment," *J Occup Health.*, vol. 49, no. 6, pp. 482-92, 2007.
- [28] M. Tischer, S. Bredendiek- Kämper and U. Poppek, "Evaluation of the HSE COSHH Essentials Exposure Predictive Model on the Basis of BAuA Field Studies and Existing Substances Exposure Data," *Ann. Occup. Hyg.*, vol. 47, no. 7, pp. 557-569, 2003.
- [29] E. Lee, J. Slaven, R. Bowen and M. Harper, "Evaluation of the COSHH Essentials model with a mixture of organic chemicals at a medium-sized paint producer," *Ann. Occup. Hyg.*, vol. 55, no. 1, pp. 16-29, 2011.
- [30] R. Jones and M. Nicas, "Evaluation of COSHH Essentials for Vapor Degreasing and Bag Filling Operations," *Ann. Occup. Hyg.*, vol. 50, no. 2, pp. 137-47, 2006.
- [31] "Stoffenmanager," [Online]. Available: <https://stoffenmanager.nl/Public/Explanation.aspx>.
- [32] H. Marquart, Heussen, H, M. Le Feber, D. Noy, E. Tielemans, J. Schinkel, J. West and D. Van der Schaaf, "'Stoffenmanager', a web-based control banding tool using an exposure process model," *Ann. Occup. Hyg.*, vol. 52, no. 6, pp. 429-441, 2008.
- [33] E. Tielemans, D. Noy, J. Schinkel, H. Heussen, D. van der Schaaf, J. West and W. Fransman, "Stoffenmanager exposure model: development of a quantitative algorithm," *Ann. Occup. Hyg.*, vol. 52, no. 6, pp. 443-454, 2008.
- [34] J. Schinkel, W. Fransman, H. Heussen, H. Kromhout, H. Marquart and E. Tielemans, "Cross-validation and refinement of the Stoffenmanager as a first tier exposure assessment tool for REACH," *Occup. Environ. Med.*, vol. 67, no. 2, pp. 125-32, 2010.
- [35] D. Koppisch, J. Schinkel, S. Gabriel, W. Fransman and E. Tielemans, "Use of the MEGA exposure database for the validation of the Stoffenmanager model," *Ann. Occup. Hyg.*, vol. 56, no. 4, pp. 426-39, 2012.
- [36] J. Lamb, B. G. Miller, L. MacCalman, S. Rashid and M. van Tongeren, "Evaluation of Tier 1 Exposure Assessment Models under REACH (etteam) Project - Substudy Report on External Validation Exercise," 2015. [Online]. Available:

<http://www.baua.de/en/Publications/Expert-Papers/F2303-D16.html>.

- [37] H. E. Landberg, P. Berg, L. Andersson, U. Bergendorf, J. Karlsson, H. Westberg and H. Tinnerberg, "Comparison and Evaluation of Multiple Users' Usage of the Exposure and Risk Tool: Stoffenmanager 5.1.," *Ann. Occup. Hyg.*, vol. 59, no. 7, pp. 821-835, 2015.
- [38] N. Warren, H. Marquart, Y. Christopher, J. Laitinen and J. Van Hemmen, "Task-based dermal exposure models for regulatory risk assessment," *Ann. Occup. Hyg.*, vol. 42, no. 6, pp. 391-400, 2006.
- [39] E. Tielemans, N. Warren, T. Schneider, M. Tischer, P. Ritchie, H. Goede, H. Kromhout, J. Van Hemmen and J. Cherrie, "Tools for regulatory assessment of occupational exposure -development and challenges," *Journal of Exposure Science and Environmental Epidemiology* , vol. 17, p. S72–S80, 2007.
- [40] EC, *Commission directive 2000/39/EC establishing a first list of indicative occupational exposure limit values in implementation of Council directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at w*, 2000.
- [41] EC, *Council Directive 98/24/EC of 7 April 1998 on the protection of the health and safety of workers from the risks related to chemical agents at work*, 1998.
- [42] HSE (Health and Safety Executive), "Approved Code of Practice and guidance," 2013. [Online]. Available: <http://www.hse.gov.uk/pubns/books/l5.htm>.

1
2
3
4
5
6
7

EUROPEAN CHEMICALS AGENCY
ANNANKATU 18, P.O. BOX 400,
FI-00121 HELSINKI, FINLAND
ECHA.EUROPA.EU